polymer - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	polymer	go back to main search page
Accession:	CHEBI:60027	browse the term
Definition:	A polymer is a mixture, which is composed of macromolecules of different kinds and which may be differentiated by composition, length, degree of branching etc..
Synonyms:	related_synonym:	Kunststoff
	xref:	Wikipedia:Polymer

show annotations for term's descendants Sort by:
Rat (1026) Mouse (1049) Human (1044) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1026)

Calcium arsenate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

secretoglobin family 1A member 1

decreases expression

calcium arsenate results in decreased expression of SCGB1A1 protein

NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610

G

tumor necrosis factor

multiple interactions

[calcium arsenate results in increased abundance of Arsenic] which results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Collagen

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

discoidin domain receptor tyrosine kinase 1

increases phosphorylation
increases expression

collagen increases autophosphorylation of DDR1 in U2OS cells
collagen increases phosphorylation of DDR1 in human melanoma cells
collagen increases expression of DDR1 mRNA in human renal cancer cells

RGD

PMID:24768818 PMID:31271515 PMID:27020590

RGD:151347549, RGD:151347864, RGD:151347863

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

Hexadimethrine bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-X-C motif chemokine ligand 1

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CXCL1 mRNA]

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

coagulation factor III, tissue factor

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fibroblast growth factor 2

decreases response to substance

Hexadimethrine Bromide results in decreased susceptibility to FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

high mobility group box 1

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

interleukin 1 alpha

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 6

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

serpin family E member 1

multiple interactions

Hexadimethrine Bromide inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of SERPINE1 mRNA]

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

lentinan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression

Lentinan results in decreased expression of CYP1A1

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression

Lentinan results in decreased expression of CYP1A2

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

mitogen activated protein kinase 1

multiple interactions

Lentinan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Lentinan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nitric oxide synthase 2

multiple interactions

Lentinan inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Lentinan inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

RELA proto-oncogene, NF-kB subunit

increases activity
multiple interactions

Lentinan results in increased activity of RELA
Lentinan promotes the reaction [Lipopolysaccharides results in increased localization of RELA protein]

PMID:15630237 PMID:22102286

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions
increases expression

Lentinan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lentinan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Lentinan results in increased expression of TNF

PMID:15630237 PMID:22102286

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

mancozeb

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

affects activity
multiple interactions

mancozeb affects the activity of ACHE protein
[carbendazim co-treated with mancozeb] results in increased activity of ACHE protein

PMID:10641187 PMID:33217513

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

actin, gamma 1

increases expression

mancozeb results in increased expression of ACTG1 protein

NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
Ensembl chr 3:105,619,737...105,624,232

G

actin maturation protease

decreases expression

mancozeb results in decreased expression of ACTMAP mRNA

NCBI chr 1:82,490,313...82,499,841
Ensembl chr 1:82,490,363...82,499,841

G

AKT serine/threonine kinase 1

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

decreases expression

mancozeb results in decreased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 2 family member

decreases activity
multiple interactions

mancozeb results in decreased activity of ALDH2 protein
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

PMID:17010440 PMID:34830855

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 5 family, member A1

decreases activity

mancozeb results in decreased activity of ALDH5A1 protein

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

angiopoietin-like 1

decreases expression

mancozeb results in decreased expression of ANGPTL1 mRNA

NCBI chr13:68,963,186...68,981,649
Ensembl chr13:68,962,991...68,992,570

G

annexin A2

decreases expression

mancozeb results in decreased expression of ANXA2 protein

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

androgen receptor

multiple interactions
decreases expression
decreases activity

mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein]
mancozeb results in decreased expression of AR mRNA
mancozeb results in decreased activity of AR protein

PMID:23871939 PMID:33396126

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ATPase Na+/K+ transporting subunit alpha 2

decreases expression

mancozeb results in decreased expression of ATP1A2 mRNA

NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

mancozeb results in increased expression of BAX mRNA
mancozeb results in increased expression of BAX protein
[Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BAX mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BAX mRNA; lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA]

PMID:27235710 PMID:35564597 PMID:35617905

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

mancozeb results in decreased expression of BCL2 mRNA
mancozeb results in decreased expression of BCL2 protein
[Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BCL2 mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BCL2 mRNA; lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA]
alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein]

PMID:16005924 PMID:27235710 PMID:35564597 PMID:35617905

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

carbonic anhydrase 3

increases expression

mancozeb results in increased expression of CAR3 protein

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

caspase 3

increases activity
increases expression
multiple interactions
increases cleavage

mancozeb results in increased activity of CASP3 protein
mancozeb results in increased expression of CASP3 protein
Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein]

PMID:22824503 PMID:30037311 PMID:35617905

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity

mancozeb results in increased activity of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity

mancozeb results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
increases expression

mancozeb results in increased activity of CASP9 protein
mancozeb results in increased expression of CASP9 protein

PMID:22824503 PMID:35617905

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
decreases activity

Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein]
Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein]

PMID:23024109 PMID:27235710 PMID:29283200 PMID:30037311 PMID:35617905 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 106

decreases expression

mancozeb results in decreased expression of CCDC106 mRNA

NCBI chr 1:68,779,882...68,783,975
Ensembl chr 1:68,779,882...68,786,846

G

cyclin D1

multiple interactions
increases expression

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein
mancozeb results in increased expression of CCND1 protein

PMID:19883720 PMID:21375462

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cell division cycle 25C

increases phosphorylation

mancozeb results in increased phosphorylation of CDC25C protein

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cilia and flagella associated protein 126

decreases expression

mancozeb results in decreased expression of CFAP126 mRNA

NCBI chr13:83,526,657...83,542,552
Ensembl chr13:83,526,657...83,542,552

G

claudin 16

decreases expression

mancozeb results in decreased expression of CLDN16 mRNA

NCBI chr11:74,290,298...74,309,588
Ensembl chr11:74,290,298...74,309,588

G

cardiotrophin 1

decreases expression

mancozeb results in decreased expression of CTF1 mRNA

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

cytochrome c, somatic

increases expression

mancozeb results in increased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity
decreases expression

mancozeb results in decreased activity of CYP1A1 protein
mancozeb results in decreased expression of CYP1A1 protein

PMID:1946188 PMID:31096615

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases expression

mancozeb results in decreased expression of CYP2B6 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression

mancozeb results in decreased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression

mancozeb results in decreased expression of CYP3A4 mRNA; mancozeb results in decreased expression of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage-inducible transcript 4

increases expression

mancozeb results in increased expression of DDIT4 protein

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DNA methyltransferase 1

decreases expression

mancozeb results in decreased expression of DNMT1 protein

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 alpha

decreases expression

mancozeb results in decreased expression of DNMT3A protein

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

dual specificity phosphatase 1

decreases expression

mancozeb results in decreased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

EF-hand calcium binding domain 12

decreases expression

mancozeb results in decreased expression of EFCAB12 mRNA

NCBI chr 4:148,869,381...148,892,922
Ensembl chr 4:148,869,387...148,890,560

G

ephrin A1

decreases expression

mancozeb results in decreased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin A3

decreases expression

mancozeb results in decreased expression of EFNA3 mRNA

NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736

G

ETS transcription factor ELK1

increases phosphorylation

mancozeb results in increased phosphorylation of ELK1 protein

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

estrogen receptor 1

decreases expression

mancozeb results in decreased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

decreases expression

mancozeb results in decreased expression of ESR2 mRNA; mancozeb results in decreased expression of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

coagulation factor III, tissue factor

increases expression

mancozeb results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

mancozeb results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions
decreases expression
increases expression

lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA]
mancozeb results in decreased expression of GADD45A mRNA

PMID:27235710 PMID:36007320

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glycine-N-acyltransferase-like 3

decreases expression

mancozeb results in decreased expression of GLYATL3 mRNA

NCBI chr 9:19,977,493...19,995,723
Ensembl chr 9:19,977,302...19,995,650

G

glutamic-oxaloacetic transaminase 1

affects activity

mancozeb affects the activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

affects activity
multiple interactions

mancozeb affects the activity of GPT protein
[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein; Resveratrol inhibits the reaction [[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein]

PMID:10641187 PMID:37009748

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

decreases expression
multiple interactions

mancozeb results in decreased expression of GPX1 mRNA
Acetylcysteine inhibits the reaction [mancozeb results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glycogen synthase kinase 3 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

histone deacetylase 3

decreases activity

mancozeb results in decreased activity of HDAC3 protein

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 6

decreases activity

mancozeb results in decreased activity of HDAC6 protein

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

heterogeneous nuclear ribonucleoprotein M

increases expression

mancozeb results in increased expression of HNRNPM protein

NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762

G

heat shock protein family A (Hsp70) member 1B

increases expression

mancozeb results in increased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

interferon induced transmembrane protein 2

decreases expression

mancozeb results in decreased expression of IFITM2 mRNA

NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741

G

interferon gamma

multiple interactions

mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

affects expression

mancozeb affects the expression of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

integrin subunit beta 3

decreases expression

mancozeb results in decreased expression of ITGB3 mRNA; mancozeb results in decreased expression of ITGB3 protein

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

potassium voltage-gated channel subfamily Q member 2

increases activity

mancozeb results in increased activity of KCNQ2 protein

NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071

G

KiSS-1 metastasis-suppressor

affects expression

mancozeb affects the expression of KISS1 mRNA

NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612

G

leukotriene B4 receptor 2

increases expression

mancozeb results in increased expression of LTB4R2 mRNA

NCBI chr15:29,258,712...29,260,531
Ensembl chr15:29,259,240...29,260,316

G

mitogen-activated protein kinase kinase kinase 5

increases expression

mancozeb results in increased expression of MAP3K5 mRNA

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen-activated protein kinase kinase kinase 6

increases expression

mancozeb results in increased expression of MAP3K6 mRNA

NCBI chr 5:145,440,126...145,452,213
Ensembl chr 5:145,440,346...145,452,212

G

mitogen activated protein kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MDM2 proto-oncogene

multiple interactions
increases expression

lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

mitochondrially encoded cytochrome b

decreases expression

mancozeb results in decreased expression of CYTB mRNA

NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3

decreases expression

mancozeb results in decreased expression of ND3 mRNA

NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
NCBI chr MT:9,451...9,798
Ensembl chr MT:9,451...9,798

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L

decreases expression

mancozeb results in decreased expression of ND4L mRNA

NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

decreases expression

mancozeb results in decreased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

mucin 1, cell surface associated

decreases expression

mancozeb results in decreased expression of MUC1 mRNA; mancozeb results in decreased expression of MUC1 protein

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression
increases expression

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein
mancozeb results in decreased expression of MYC mRNA
mancozeb results in increased expression of MYC protein
mancozeb results in decreased expression of MYC protein
alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein]

PMID:16005924 PMID:19883720 PMID:36007320

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NHL repeat containing E3 ubiquitin protein ligase 1

decreases expression

mancozeb results in decreased expression of NHLRC1 mRNA

NCBI chr17:17,674,303...17,677,144
Ensembl chr17:17,674,319...17,677,148

G

nitric oxide synthase 2

increases expression
multiple interactions

mancozeb results in increased expression of NOS2 mRNA
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NADPH oxidase 4

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOX4 mRNA]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nuclear receptor subfamily 4, group A, member 1

decreases expression

mancozeb results in decreased expression of NR4A1 mRNA

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

ornithine decarboxylase 1

increases activity

mancozeb results in increased activity of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

8-oxoguanine DNA glycosylase

multiple interactions
decreases expression

lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA]

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

olfactory receptor family 1 subfamily S member 2

increases expression

mancozeb results in increased expression of OR1S1 mRNA

NCBI chr 1:210,913,992...210,914,939
Ensembl chr 1:210,911,289...210,915,657

G

Parkinsonism associated deglycase

multiple interactions

mancozeb results in decreased activity of and results in increased oxidation of PARK7 protein

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

protocadherin beta 20

decreases expression

mancozeb results in decreased expression of PCDHB14 mRNA

NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,211,883...29,215,258

G

peroxiredoxin 2

increases expression

mancozeb results in increased expression of PRDX2 protein

NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194

G

prolactin

multiple interactions
increases expression

[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein
mancozeb results in increased expression of PRL mRNA

PMID:24530807 PMID:33396126

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prostaglandin E synthase

increases expression
decreases expression
multiple interactions

mancozeb results in increased expression of PTGES mRNA
mancozeb results in decreased expression of PTGES protein
lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA]

PMID:27235710 PMID:32446389

NCBI chr 3:14,177,892...14,189,236

G

prostaglandin E synthase 3

decreases expression

mancozeb results in decreased expression of PTGES3 mRNA

NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084

G

prostaglandin-endoperoxide synthase 2

increases expression

mancozeb results in increased expression of PTGS2 protein

PMID:21375462 PMID:32446389

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

parvalbumin

increases expression

mancozeb results in increased expression of PVALB protein

NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
affects localization
multiple interactions

mancozeb results in increased phosphorylation of RELA protein
mancozeb affects the localization of RELA protein
Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]

PMID:16112155 PMID:21375462 PMID:27235710

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

S100 calcium binding protein A6

increases expression

mancozeb results in increased expression of S100A6 protein

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A9

increases expression

mancozeb results in increased expression of S100A9 protein

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

scleraxis bHLH transcription factor

decreases expression

mancozeb results in decreased expression of SCX mRNA

NCBI chr 7:108,176,608...108,178,626
Ensembl chr 7:108,176,608...108,178,626

G

succinate dehydrogenase complex subunit C

decreases expression

mancozeb results in decreased expression of SDHC mRNA

NCBI chr13:83,544,652...83,565,560
Ensembl chr13:83,544,652...83,566,253

G

septin 11

increases expression

mancozeb results in increased expression of SEPTIN11 mRNA

NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853

G

serpin family F member 1

decreases expression

mancozeb results in decreased expression of SERPINF1 mRNA

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

sirtuin 1

decreases activity

mancozeb results in decreased activity of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

decreases activity

mancozeb results in decreased activity of SIRT2 protein

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

decreases activity

mancozeb results in decreased activity of SIRT3 protein

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 14 member 1 (Kidd blood group)

decreases expression

mancozeb results in decreased expression of SLC14A1 mRNA

NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146

G

solute carrier family 5 member 5

multiple interactions

mancozeb inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine]

NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697

G

small nucleolar RNA, C/D box 82

increases expression

mancozeb results in increased expression of SNORD82 mRNA

NCBI chr 9:87,004,515...87,004,586
Ensembl chr 9:87,004,515...87,004,586

G

superoxide dismutase 1

decreases expression
decreases activity

mancozeb results in decreased expression of SOD1 protein
mancozeb results in decreased activity of SOD1 protein

PMID:21375462 PMID:35617905

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

sulfotransferase family 2B member 1

decreases expression

mancozeb results in decreased expression of SULT2B1 mRNA

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

G

TEK receptor tyrosine kinase

increases activity

mancozeb results in increased activity of TEK protein

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804

G

transforming growth factor beta 1 induced transcript 1

decreases expression

mancozeb results in decreased expression of TGFB1I1 mRNA

NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080

G

tumor necrosis factor

multiple interactions

mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein]
mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein]

PMID:15742816 PMID:15893782 PMID:16112155

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression
increases expression
multiple interactions

mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein
mancozeb results in increased expression of TP53 mRNA
lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA]

PMID:22369882 PMID:27235710

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

increases expression

mancozeb results in increased expression of TPI1 protein

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

thyroid peroxidase

decreases activity

mancozeb results in decreased activity of TPO protein

NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199

G

thyroid stimulating hormone subunit beta

multiple interactions

[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

X-ray repair cross complementing 1

decreases expression
multiple interactions

mancozeb results in decreased expression of XRCC1 mRNA
lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA]

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

G

zinc finger protein 358

decreases expression

mancozeb results in decreased expression of ZNF358 mRNA

NCBI chr12:1,552,367...1,556,460
Ensembl chr12:1,552,366...1,556,460

maneb

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AP2 associated kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AAK1 mRNA

NCBI chr 4:119,300,128...119,451,834
Ensembl chr 4:119,295,257...119,450,969

G

aminoadipate-semialdehyde synthase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AASS mRNA

NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136

G

4-aminobutyrate aminotransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABAT mRNA

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily A member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCA5 mRNA

NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976

G

ATP binding cassette subfamily D member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCD2 mRNA

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

abhydrolase domain containing 8

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABHD8 mRNA

NCBI chr16:18,144,464...18,151,201
Ensembl chr16:18,144,464...18,157,667

G

abl-interactor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABI2 mRNA

NCBI chr 9:61,827,186...61,905,703
Ensembl chr 9:61,827,139...61,905,699

G

ABI family member 3 binding protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABI3BP mRNA

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

actin binding LIM protein family, member 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABLIM2 mRNA

NCBI chr14:74,865,409...74,990,334
Ensembl chr14:74,866,281...74,990,334

G

acyl-CoA dehydrogenase short chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

angiotensin I converting enzyme

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACE mRNA

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acetylcholinesterase

decreases expression
multiple interactions

Maneb results in decreased expression of ACHE protein
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA

PMID:3868355 PMID:23017109

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aconitase 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin-like 6B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACTL6B mRNA

NCBI chr12:19,124,887...19,141,419
Ensembl chr12:19,124,916...19,141,376

G

adenosine deaminase-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADAL mRNA

NCBI chr 3:108,101,857...108,119,557
Ensembl chr 3:108,101,857...108,118,516
Ensembl chr 3:108,101,857...108,118,516

G

ADAM metallopeptidase domain 11

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADAM11 mRNA

NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562

G

ADAM metallopeptidase domain 22

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA

NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962

G

adenosine deaminase, RNA-specific

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADAR mRNA

NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282

G

adenylate cyclase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADCY2 mRNA

NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236

G

adhesion G protein-coupled receptor B1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adhesion G protein-coupled receptor B2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADGRB2 mRNA

NCBI chr 5:142,299,190...142,362,540
Ensembl chr 5:142,331,329...142,362,540

G

adhesion G protein-coupled receptor G1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adhesion G protein-coupled receptor L3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADGRL3 mRNA

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860

G

adrenomedullin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A1 receptor

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

ALF transcription elongation factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AFF3 mRNA

NCBI chr 9:40,399,099...40,856,716
Ensembl chr 9:40,404,375...40,857,247

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AFG3L2 mRNA

NCBI chr18:60,954,268...60,999,110
Ensembl chr18:60,954,268...60,999,110

G

argonaute RISC catalytic component 3

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA

NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230

G

allograft inflammatory factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein]

PMID:28202386 PMID:32375810

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

adherens junctions associated protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AJAP1 mRNA

NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317

G

adenylate kinase 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AK5 mRNA

NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458

G

aldo-keto reductase family 1 member B1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AKR1B1 mRNA

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

AKT serine/threonine kinase 1

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]

PMID:19883720 PMID:23963992

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

5'-aminolevulinate synthase 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

albumin

increases secretion

Maneb results in increased secretion of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 2 family member

decreases activity
multiple interactions

Maneb results in decreased activity of ALDH2 protein
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

PMID:17010440 PMID:34830855

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 5 family, member A1

decreases activity
multiple interactions

Maneb results in decreased activity of ALDH5A1 protein
[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]

PMID:17010440 PMID:23963992

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

aldolase, fructose-bisphosphate C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

alsin Rho guanine nucleotide exchange factor ALS2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ALS2 mRNA

NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737

G

adhesion molecule with Ig like domain 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AMIGO2 mRNA

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

amnion associated transmembrane protein

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of AMN mRNA

NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815

G

adenosine monophosphate deaminase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angel homolog 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANGEL1 mRNA

NCBI chr 6:106,349,125...106,386,202
Ensembl chr 6:106,349,126...106,386,209

G

ankyrin repeat domain 13D

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKRD13D mRNA

NCBI chr 1:201,565,712...201,577,987
Ensembl chr 1:201,565,712...201,577,933

G

ankyrin repeat domain containing 26

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKRD26 mRNA

NCBI chr 4:151,670,604...151,740,032
Ensembl chr 4:151,672,037...151,739,968

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

anoctamin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANO3 mRNA

NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154

G

adaptor related protein complex 3 subunit beta 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA

NCBI chr 1:135,412,580...135,445,191
Ensembl chr 1:135,412,580...135,445,191

G

adaptor related protein complex 3 subunit delta 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA

NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643

G

amyloid beta precursor protein binding family B member 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA

NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627

G

activity-regulated cytoskeleton-associated protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARC mRNA

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

ADP-ribosylation factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARF3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA

PMID:18386188 PMID:36117858

NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002

G

arginase 1

decreases expression
multiple interactions

Maneb results in decreased expression of ARG1 mRNA
[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA]

PMID:29568078 PMID:32194361 PMID:32375810 PMID:34052309

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho GTPase activating protein 26

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP26 mRNA

NCBI chr18:30,835,806...31,237,945
Ensembl chr18:30,838,671...31,235,194

G

Rho GTPase activating protein 32

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP32 mRNA

NCBI chr 8:30,421,269...30,681,653
Ensembl chr 8:30,421,515...30,678,454

G

Rho GTPase activating protein 44

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP44 mRNA

NCBI chr10:49,655,583...49,822,876
Ensembl chr10:49,655,584...49,824,297

G

ADP-ribosylation factor like GTPase 5A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARL5A mRNA

NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211

G

aryl hydrocarbon receptor nuclear translocator 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA

NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153

G

aristaless related homeobox

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARX mRNA

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142

G

N-acylsphingosine amidohydrolase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ASAH2 mRNA

NCBI chr 1:229,865,662...229,973,253
Ensembl chr 1:229,865,662...229,939,162

G

activating signal cointegrator 1 complex subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ASCC1 mRNA

NCBI chr20:27,941,053...28,031,272
Ensembl chr20:27,941,283...28,031,272

G

achaete-scute family bHLH transcription factor 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA

NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993

G

asporin

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ASPN mRNA

NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041

G

ATPase family, AAA domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

autophagy related 12

multiple interactions

Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein]

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 16-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATG16L2 mRNA

NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420

G

atos homolog A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM214A mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATP synthase F1 subunit alpha

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]

NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794

G

ATP synthase membrane subunit c locus 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit B

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA

NCBI chr 5:131,423,384...131,424,900
Ensembl chr 5:131,423,387...131,426,401

G

ATPase H+ transporting V0 subunit C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA

NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500

G

ATPase H+ transporting V1 subunit C1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]

NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278

G

ATPase phospholipid transporting 8A2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ATP8A2 mRNA

NCBI chr15:33,817,309...34,350,193
Ensembl chr15:33,819,755...34,350,223

G

ataxin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

apoptosis and caspase activation inhibitor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AVEN mRNA

NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634

G

Beta-1,3-galactosyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GALT1 mRNA

NCBI chr 3:52,253,413...52,826,508
Ensembl chr 3:52,253,618...52,825,313

G

Beta-1,3-galactosyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GALT2 mRNA

NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419

G

beta-1,3-glucuronyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GAT2 mRNA

NCBI chr 9:26,167,174...26,250,153
Ensembl chr 9:26,167,174...26,250,153

G

beta-1,4-galactosyltransferase 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B4GALT5 mRNA

NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074

G

BCL2-associated agonist of cell death

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BAH domain and coiled-coil containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BAHCC1 mRNA

NCBI chr10:105,526,309...105,583,320
Ensembl chr10:105,522,172...105,583,317

G

BCL2-antagonist/killer 1

multiple interactions
increases expression
affects response to substance

[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb]
Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein

PMID:18266926 PMID:23963992

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb]
[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]
Maneb results in increased expression of BAX protein

PMID:15824117 PMID:18266926 PMID:20964710 PMID:23963992

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression
multiple interactions

Maneb results in increased expression of BBC3 protein
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]; [Paraquat co-treated with Maneb] results in increased expression of BBC3 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]

PMID:18266926 PMID:34897981

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCAS3, microtubule associated cell migration factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of BCAS3 mRNA

NCBI chr10:70,213,710...70,673,080
Ensembl chr10:70,214,098...70,673,080

G

branched chain amino acid transaminase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

branched chain keto acid dehydrogenase E1 subunit beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCKDHB mRNA

NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812

G

BCL11 transcription factor A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCL11A mRNA

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL2, apoptosis regulator

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]
Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein

PMID:18266926 PMID:23963992 PMID:36117858

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

increases expression
multiple interactions

Maneb results in increased expression of BCL2A1 mRNA
[Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

multiple interactions
increases expression

[Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein
Maneb results in increased expression of BCL2L1 mRNA

PMID:15824117 PMID:18266926

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

increases expression
multiple interactions

Maneb results in increased expression of BCL2L11 protein
[Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA
[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF protein]

PMID:23017109 PMID:27460631 PMID:33368748 PMID:36117858

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

increases expression
multiple interactions

Maneb results in increased expression of BECN1 protein
[Paraquat co-treated with Maneb] results in increased expression of BECN1 protein

PMID:22292029 PMID:26884967

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BEN domain containing 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BEND7 mRNA

NCBI chr17:73,483,212...73,566,221
Ensembl chr17:73,485,282...73,567,559

G

brain expressed X-linked 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BEX1 mRNA

NCBI chr X:99,019,847...99,021,375
Ensembl chr X:99,019,000...99,021,503

G

BICD cargo adaptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BICD1 mRNA; [Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA

PMID:22563483 PMID:36117858

NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434

G

BICRA like chromatin remodeling complex associated protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BICRAL mRNA

NCBI chr 9:14,100,253...14,185,368
Ensembl chr 9:14,154,209...14,183,671

G

BH3 interacting domain death agonist

increases expression
multiple interactions

Maneb results in increased expression of BID protein
[Maneb co-treated with Paraquat] results in increased expression of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

BCL2-interacting killer

increases expression
multiple interactions

Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein
[Paraquat co-treated with Maneb] results in increased expression of BIK protein

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

bridge-like lipid transfer protein family member 3B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UHRF1BP1L mRNA

NCBI chr 7:24,181,635...24,261,720
Ensembl chr 7:24,181,644...24,261,720

G

bone morphogenetic protein 2

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

base methyltransferase of 25S rRNA 2 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of BMT2 mRNA

NCBI chr 4:41,881,630...41,945,472
Ensembl chr 4:41,879,993...41,945,539

G

BCL2 interacting protein 3

increases expression

Maneb results in increased expression of BNIP3 mRNA; Maneb results in increased expression of BNIP3 protein

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

increases expression

Maneb results in increased expression of BNIP3L mRNA

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

B-Raf proto-oncogene, serine/threonine kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BRAF mRNA

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

BRF1, RNA polymerase III transcription initiation factor subunit

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA

NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278

G

BR serine/threonine kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BRSK2 mRNA

NCBI chr 1:197,035,505...197,088,624
Ensembl chr 1:197,035,633...197,088,092

G

BTB domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BTBD3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of BTBD3 mRNA

NCBI chr 3:125,591,427...125,621,660
Ensembl chr 3:125,591,490...125,619,038

G

C1q and TNF related 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of C1QTNF4 mRNA

NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139

G

C2 calcium-dependent domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of C2CD5 mRNA

NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNA1C mRNA

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 E

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA

NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450

G

calcium voltage-gated channel auxiliary subunit beta 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNB2 mRNA

NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106

G

calcium voltage-gated channel auxiliary subunit gamma 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNG4 mRNA

NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126

G

calcyclin binding protein

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

calcium dependent secretion activator 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CADPS2 mRNA

NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829

G

calbindin 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CALB2 mRNA

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

calmodulin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calmodulin 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calneuron 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CALN1 mRNA

NCBI chr12:25,811,743...26,303,670
Ensembl chr12:25,819,628...26,303,344

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAMK4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

cathelicidin antimicrobial peptide

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA
[Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA

PMID:22563483 PMID:27460631

NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543

G

calpain 11

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA

NCBI chr 9:15,344,059...15,365,604
Ensembl chr 9:15,344,089...15,365,601

G

calpain 15

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CAPN15 mRNA

NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508

G

carbonic anhydrase 14

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAR14 mRNA

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

carbonic anhydrase 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAR7 mRNA

NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467

G

capping protein regulator and myosin 1 linker 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CARMIL3 mRNA

NCBI chr15:28,978,440...28,995,865
Ensembl chr15:28,979,007...28,996,225

G

caspase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein; [Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]

PMID:23963992 PMID:32375810 PMID:34052309

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases activity
multiple interactions

Maneb results in increased activity of CASP3 protein
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; [Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]

PMID:22824503 PMID:34897981

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity

Maneb results in increased activity of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity

Maneb results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]
Maneb results in increased activity of CASP9 protein

PMID:20964710 PMID:22824503 PMID:23963992

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calsequestrin 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CASQ2 mRNA

NCBI chr 2:189,526,003...189,582,276
Ensembl chr 2:189,525,960...189,582,267

G

cytosolic arginine sensor for mTORC1 subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GATSL2 mRNA

NCBI chr12:22,577,504...22,620,182
Ensembl chr12:22,577,512...22,620,182

G

catalase

decreases activity
multiple interactions

Maneb results in decreased activity of CAT protein
[Maneb co-treated with Paraquat] results in increased expression of CAT mRNA

PMID:26210702 PMID:28322069 PMID:29859004

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 148

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC148 mRNA

NCBI chr 3:43,356,885...43,631,999
Ensembl chr 3:43,356,892...43,631,991

G

coiled-coil domain containing 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC6 mRNA

NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658

G

coiled coil domain containing 88A

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA

NCBI chr14:103,104,091...103,256,112
Ensembl chr14:103,103,513...103,252,368

G

coiled-coil domain containing 88C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC88C mRNA

NCBI chr 6:120,169,752...120,289,459
Ensembl chr 6:120,169,738...120,289,555

G

coiled-coil domain containing 92

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC92 mRNA

NCBI chr12:31,796,102...31,823,333
Ensembl chr12:31,796,684...31,823,337

G

cholecystokinin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCK mRNA

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 19

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA

NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 21

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA

NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686

G

cyclin D1

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein
[Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA

PMID:19883720 PMID:29859004

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

centriolar coiled-coil protein 110

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCP110 mRNA

NCBI chr 1:173,042,238...173,072,873
Ensembl chr 1:173,042,310...173,072,873

G

CD24 molecule

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CD24A mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD34 molecule

increases expression

Maneb results in increased expression of CD34

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

Cd68 molecule

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

cell division cycle associated 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDCA7 mRNA

NCBI chr 3:57,322,718...57,333,353
Ensembl chr 3:57,322,708...57,333,353

G

cadherin 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDH7 mRNA

NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846

G

cadherin-related family member 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA

NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA

NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408

G

cyclin dependent kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 5 regulatory subunit 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA

NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456

G

CDK5 regulatory subunit associated protein 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA

NCBI chr 3:142,838,081...142,872,669
Ensembl chr 3:142,708,028...142,872,677

G

CDK5 regulatory subunit associated protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]

NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA
Maneb results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cysteine dioxygenase type 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDO1 mRNA

NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296

G

CDP-diacylglycerol synthase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

CCAAT/enhancer binding protein delta

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CELF3 mRNA

NCBI chr 2:182,116,034...182,130,163
Ensembl chr 2:182,116,073...182,130,163

G

cell cycle exit and neuronal differentiation 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CEND1 mRNA

NCBI chr 1:196,525,153...196,528,152
Ensembl chr 1:196,523,920...196,528,302

G

centromere protein C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CENPC1 mRNA

NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476

G

centrosomal protein 290

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA

NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392

G

centrosomal protein 295

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CEP295 mRNA

NCBI chr 8:12,156,568...12,194,542
Ensembl chr 8:12,156,554...12,194,552

G

cerebral endothelial cell adhesion molecule

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CERCAM mRNA

NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956

G

chromatin assembly factor 1 subunit A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromogranin A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHGA mRNA

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

chondroitin polymerizing factor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHPF2 mRNA

NCBI chr 4:10,578,470...10,585,940
Ensembl chr 4:10,580,462...10,585,916

G

chordin-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHRDL1 mRNA

NCBI chr X:106,889,125...106,992,937
Ensembl chr X:106,889,125...106,992,921

G

cholinergic receptor, muscarinic 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

circadian associated repressor of transcription

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CIART mRNA

NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313

G

ciliary microtubule associated protein 1B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ODF3B mRNA

NCBI chr 7:120,444,232...120,447,294
Ensembl chr 7:120,444,232...120,446,749

G

cold inducible RNA binding protein

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

creatine kinase, mitochondrial 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CKMT1 mRNA

NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

chloride channel accessory 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA]

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride voltage-gated channel 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLCN5 mRNA

NCBI chr X:15,185,380...15,339,977
Ensembl chr X:15,185,451...15,334,264

G

chloride voltage-gated channel 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CLCN7 mRNA

NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130

G

claudin 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLDN12 mRNA

NCBI chr 4:28,522,659...28,533,647
Ensembl chr 4:28,522,678...28,533,801

G

C-type lectin domain containing 16A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CLEC16A mRNA

NCBI chr10:4,927,799...5,123,749
Ensembl chr10:4,928,030...5,123,578

G

CAP-GLY domain containing linker protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLIP2 mRNA

NCBI chr12:22,163,044...22,227,023
Ensembl chr12:22,163,218...22,227,023

G

CAP-GLY domain containing linker protein family, member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLIP4 mRNA

NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874

G

CXADR-like membrane protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLMP mRNA

NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838

G

clusterin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

carboxymethylenebutenolidase homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CMBL mRNA

NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009

G

cornichon family AMPA receptor auxiliary protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CNIH2 mRNA

NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089

G

cornichon family AMPA receptor auxiliary protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CNIH3 mRNA

NCBI chr13:93,016,707...93,208,168
Ensembl chr13:93,099,784...93,208,121

G

centrobin, centriole duplication and spindle assembly protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CNTROB mRNA

NCBI chr10:54,022,523...54,047,793
Ensembl chr10:54,022,852...54,044,849

G

collagen type XIV alpha 1 chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COL14A1 mRNA

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type I alpha 1 chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

COPI coat complex subunit epsilon

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA

NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907

G

cytochrome c oxidase subunit 5A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]

NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781

G

cytochrome c oxidase subunit 6A1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA

NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041

G

cytochrome c oxidase subunit 6B1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001

G

cytochrome c oxidase subunit 7A1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX7A1 mRNA

NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151

G

cytochrome c oxidase subunit 7A2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA

NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
Ensembl chr 8:51,301,168...51,301,633

G

cytochrome c oxidase subunit 7A2 like

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA

NCBI chr 6:11,184,064...11,198,287
Ensembl chr 6:11,184,285...11,198,273

G

complexin 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein

NCBI chr14:1,184,677...1,216,392

G

copine 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE4 mRNA

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

copine 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE5 mRNA

NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883

G

copine 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE6 mRNA

NCBI chr15:28,998,293...29,005,044
Ensembl chr15:28,998,293...29,005,044

G

copine 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE7 mRNA

NCBI chr19:51,164,316...51,182,676
Ensembl chr19:51,166,034...51,182,677

G

cAMP responsive element binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA]

PMID:23963992 PMID:27460631 PMID:33368748

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cysteine-rich protein 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

cytokine receptor-like factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CRLF1 mRNA

NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997

G

cytokine receptor-like factor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CRLF2 mRNA; [Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA

PMID:22563483 PMID:36117858

NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642

G

carnitine O-octanoyltransferase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

G

colony stimulating factor 1 receptor

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA]

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

colony stimulating factor 2 receptor subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA]

NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128

G

cathepsin L

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA]

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cortactin binding protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CTTNBP2 mRNA

NCBI chr 4:46,800,975...46,964,681
Ensembl chr 4:46,800,981...46,964,631

G

cullin 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CUL5 mRNA

NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666

G

cytochrome b-245 beta chain

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CYBB protein; [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]

PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome c-1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA

NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
decreases expression
increases expression

Maneb results in increased activity of CYP1A1 protein
Maneb results in decreased expression of CYP1A1 mRNA
Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein

PMID:20888808 PMID:32194361

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

Maneb results in decreased expression of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
decreases expression

Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions
increases activity

Maneb results in decreased activity of CYP2E1 protein
Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein
[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]
Maneb results in increased activity of CYP2E1 protein
[Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]

PMID:11043497 PMID:16510128 PMID:20888808 PMID:20964710 PMID:23159886

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Maneb results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DAB adaptor protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DAB1 mRNA

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

dishevelled-binding antagonist of beta-catenin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DACT3 mRNA

NCBI chr 1:77,546,900...77,558,631
Ensembl chr 1:77,546,900...77,558,630

G

death associated protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA]

NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461

G

diazepam binding inhibitor

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

drebrin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 12-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF12L1 mRNA

NCBI chr X:123,695,286...123,698,905
Ensembl chr X:123,695,286...123,698,905

G

DDB1 and CUL4 associated factor 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

DDB1 and CUL4 associated factor 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF6 mRNA

NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512

G

DNA cross-link repair 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

DNA-damage-inducible transcript 4

increases expression

Maneb results in increased expression of DDIT4 protein

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DEAD-box helicase 20

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDX20 mRNA

NCBI chr 2:193,158,761...193,168,484
Ensembl chr 2:193,158,823...193,166,774

G

DEAD-box helicase 25

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDX25 mRNA

NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764

G

DEAD-box helicase 5

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DENN domain containing 6B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DENND6B mRNA

NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494

G

DEP domain containing 5, GATOR1 subcomplex subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DEPDC5 mRNA

NCBI chr14:77,732,297...77,862,924
Ensembl chr14:77,732,297...77,862,794

G

desumoylating isopeptidase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DESI1 mRNA

NCBI chr 7:113,519,974...113,542,834
Ensembl chr 7:113,519,980...113,542,845

G

diacylglycerol kinase epsilon

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKE mRNA

NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100

G

diacylglycerol kinase, gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKG mRNA

NCBI chr11:78,384,212...78,579,158
Ensembl chr11:78,384,458...78,577,212

G

diacylglycerol kinase, iota

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733

G

diacylglycerol kinase, theta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKQ mRNA

NCBI chr14:1,059,125...1,073,131
Ensembl chr14:1,059,170...1,073,131

G

DExH-box helicase 34

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DHX34 mRNA

NCBI chr 1:76,880,867...76,905,148
Ensembl chr 1:76,880,867...76,905,113

G

iodothyronine deiodinase 1

decreases activity

Maneb results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

disco-interacting protein 2 homolog B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA

NCBI chr 7:131,174,575...131,350,417
Ensembl chr 7:131,174,567...131,349,092

G

DISC1 scaffold protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DISC1 mRNA

NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778

G

discs large MAGUK scaffold protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DLG3 mRNA

NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322

G

delta like canonical Notch ligand 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA

NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179

G

dihydrolipoamide S-succinyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]

NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296

G

DMRT-like family A2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA

NCBI chr 5:124,805,883...124,811,694
Ensembl chr 5:124,805,883...124,811,630

G

DnaJ heat shock protein family (Hsp40) member B6

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA

NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659

G

dynamin 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dedicator of cytokinesis 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

docking protein 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DOK7 mRNA

NCBI chr14:75,665,444...75,699,413
Ensembl chr14:75,666,744...75,699,386

G

diphthamine biosynthesis 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DPH6 mRNA

NCBI chr 3:101,307,229...101,437,463
Ensembl chr 3:101,307,231...101,534,603

G

dpy-19 like C-mannosyltransferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DPY19L3 mRNA

NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339

G

dihydropyrimidine dehydrogenase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DPYD mRNA

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

dopamine receptor D2

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D4

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DRD4 protein

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

dopamine receptor D5

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774

G

dystrophin related protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DRP2 mRNA

NCBI chr X:97,607,577...97,658,117
Ensembl chr X:97,607,719...97,655,684

G

dual specificity phosphatase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

deoxyuridine triphosphatase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DUT mRNA; [Maneb co-treated with Paraquat] results in increased expression of DUT mRNA

NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771

G

dynein cytoplasmic 1 intermediate chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DYNC1I1 mRNA

NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149

G

dynein cytoplasmic 2 light intermediate chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DYNC2LI1 mRNA

NCBI chr 6:9,992,537...10,025,355
Ensembl chr 6:9,992,541...10,025,336

G

dual specificity tyrosine phosphorylation regulated kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DYRK2 mRNA

NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106

G

E2F transcription factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

extracellular matrix protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ECM2 mRNA

NCBI chr17:15,120,194...15,152,536
Ensembl chr17:15,120,196...15,152,516

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

eukaryotic translation elongation factor 1 gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]

NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382

G

ephrin A3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EFNA3 mRNA

NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736

G

ephrin B1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

ephrin B3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EFNB3 mRNA

NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471

G

EFR3 homolog B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of EFR3B mRNA

NCBI chr 6:26,947,436...27,021,113
Ensembl chr 6:26,948,540...27,020,933

G

EGF-like-domain, multiple 8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EGFL8 mRNA

NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018

G

early growth response 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

EP300 interacting inhibitor of differentiation 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EID2 mRNA

NCBI chr 1:83,538,274...83,539,599

G

eukaryotic translation initiation factor 2 alpha kinase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EIF2AK4 mRNA

NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630

G

eukaryotic translation initiation factor 4, gamma 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA]

NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588

G

ELAV like RNA binding protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ELAVL4 mRNA

NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446

G

extracellular leucine-rich repeat and fibronectin type III domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELFN2 mRNA

NCBI chr 7:110,220,293...110,272,770
Ensembl chr 7:110,225,919...110,272,433

G

ETS transcription factor ELK1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

elongation factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ELOF1 mRNA

NCBI chr 8:20,645,336...20,650,888
Ensembl chr 8:20,645,336...20,650,579

G

ELOVL fatty acid elongase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

embigin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EMB mRNA

NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050

G

Emx2 opposite strand/antisense RNA

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EMX2OS mRNA

NCBI chr 1:258,569,637...258,626,810

G

endonuclease, poly(U)-specific

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ENDOU mRNA

NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596

G

enolase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein]

PMID:17532186 PMID:18386188 PMID:23562983

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

enolase 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ENO2 protein

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ENPP1 mRNA

NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715

G

erythrocyte membrane protein band 4.1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPB41 mRNA

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

erythrocyte membrane protein band 4.1 like 4B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPB41L4B mRNA

NCBI chr 5:71,691,706...71,852,583
Ensembl chr 5:71,694,331...71,851,990

G

Eph receptor B6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPHB6 mRNA

NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230

G

EPM2A glucan phosphatase, laforin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPM2A mRNA; [Maneb co-treated with Paraquat] results in increased expression of EPM2A mRNA

NCBI chr 1:5,727,111...5,845,338
Ensembl chr 1:5,727,066...5,920,555

G

EPM2A interacting protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

ERCC excision repair 2, TFIIH core complex helicase subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ERCC2 mRNA

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

ERCC excision repair 6 like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ERCC6L2 mRNA

NCBI chr17:1,076,486...1,311,281
Ensembl chr17:1,216,428...1,310,275

G

ERBB receptor feedback inhibitor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

enhancer trap locus 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA

NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715

G

exosome component 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EXOSC2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of EXOSC2 mRNA

NCBI chr 3:14,962,930...14,973,645
Ensembl chr 3:14,962,917...14,973,575

G

exostosin glycosyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EXT1 mRNA

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

EYA transcriptional coactivator and phosphatase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EYA1 mRNA

NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483

G

fatty acid amide hydrolase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAAH mRNA

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

family with sequence similarity 118, member B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAM118B mRNA

NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270

G

family with sequence similarity 171, member A2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM171A2 mRNA

NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053

G

family with sequence similarity 241 member B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM241B mRNA

NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084

G

family with sequence similarity 72, member A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM72A mRNA

NCBI chr13:42,967,701...42,979,083
Ensembl chr13:42,967,578...42,984,208

G

Fas cell surface death receptor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

FAT atypical cadherin 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAT4 mRNA

NCBI chr 2:121,927,266...122,056,700
Ensembl chr 2:121,927,942...122,056,707

G

F-box protein 27

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FBXO27 mRNA

NCBI chr 1:83,965,426...83,987,781
Ensembl chr 1:83,965,986...83,987,778

G

F-box protein 41

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FBXO41 mRNA

NCBI chr 4:118,007,517...118,039,547
Ensembl chr 4:118,010,978...118,039,406

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

fasciculation and elongation protein zeta 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA

NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683

G

fibroblast growth factor receptor 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA]

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

FHF complex subunit HOOK interacting protein 2B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM160B2 mRNA

NCBI chr15:45,656,641...45,674,603
Ensembl chr15:45,656,647...45,674,105

G

four and a half LIM domains 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

FKBP prolyl isomerase 4

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

FKBP prolyl isomerase 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

fibronectin leucine rich transmembrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FLRT1 mRNA

NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750

G

fibronectin leucine rich transmembrane protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FLRT2 mRNA

NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785

G

FLYWCH family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FLYWCH2 mRNA

NCBI chr10:12,798,757...12,807,082
Ensembl chr10:12,798,762...12,806,439

G

fibronectin type III domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FNDC5 mRNA

NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOS mRNA; [Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS protein]

PMID:23963992 PMID:27460631 PMID:33368748 PMID:36117858

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box K1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOXK1 mRNA

NCBI chr12:12,110,119...12,175,089
Ensembl chr12:12,115,950...12,175,089

G

FAD-dependent oxidoreductase domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOXRED2 mRNA

NCBI chr 7:109,521,761...109,538,300
Ensembl chr 7:109,521,761...109,540,874

G

FRAT regulator of WNT signaling pathway 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FRAT1 mRNA

NCBI chr 1:240,638,309...240,640,857
Ensembl chr 1:240,638,296...240,640,945

G

ferric-chelate reductase 1-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FRRS1L mRNA

NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108

G

FTX transcript, XIST regulator

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FTX mRNA

NCBI chr X:68,588,349...68,630,338

G

FXYD domain-containing ion transport regulator 6

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA

NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Maneb results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of G6PDX mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha6

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA

NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769

G

gamma-aminobutyric acid type A receptor subunit gamma 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GABRG1 mRNA

NCBI chr14:37,396,217...37,469,606
Ensembl chr14:37,396,294...37,635,956

G

cyclin G associated kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GAK mRNA

NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

gigaxonin

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GAN mRNA

NCBI chr19:45,207,783...45,265,066
Ensembl chr19:45,207,184...45,254,107

G

growth arrest specific 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA

NCBI chr13:73,303,611...73,306,932

G

growth arrest specific 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

glutamate-cysteine ligase, catalytic subunit

increases expression
increases activity

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA
Maneb results in increased activity of GCLC protein

PMID:15527874 PMID:21402726

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

guanine deaminase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDA mRNA

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

ganglioside-induced differentiation-associated protein 1-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDAP1L1 mRNA

NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711

G

growth differentiation factor 11

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDF11 mRNA

NCBI chr 7:1,311,732...1,325,211
Ensembl chr 7:1,311,732...1,320,725

G

glial fibrillary acidic protein

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

GDNF family receptor alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

GDNF family receptor alpha 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GFRA4 mRNA

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

growth hormone 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GH mRNA

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

gastrokine 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GKN3 mRNA

NCBI chr 4:119,828,859...119,833,924
Ensembl chr 4:119,829,005...119,834,842

G

glucuronic acid epimerase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GLCE mRNA

NCBI chr 8:62,546,104...62,612,144
Ensembl chr 8:62,546,107...62,612,040

G

ganglioside GM2 activator

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA

NCBI chr10:39,219,221...39,231,756
Ensembl chr10:39,219,243...39,231,757

G

glia maturation factor, beta

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein

NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331

G

G protein subunit alpha i1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNAI1 mRNA

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit alpha L

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNAL mRNA

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

G protein subunit beta 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GNB5 mRNA

NCBI chr 8:76,076,120...76,105,069
Ensembl chr 8:76,073,306...76,105,069

G

G protein subunit gamma 13

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNG13 mRNA

NCBI chr10:14,741,179...14,743,083
Ensembl chr10:14,741,239...14,743,083

G

G protein subunit gamma 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNG3 mRNA

NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603

G

G protein subunit gamma 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA

NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513

G

G protein subunit gamma transducin 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA

NCBI chr10:80,776,003...80,784,235

G

golgi associated PDZ and coiled-coil motif containing

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GOPC mRNA

NCBI chr20:31,727,617...31,776,904
Ensembl chr20:31,727,620...31,776,903

G

glycerophosphocholine phosphodiesterase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GPCPD1 mRNA

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

G protein-coupled receptor 22

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPR22 mRNA

NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486

G

G protein-coupled receptor 27

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA

NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497

G

G protein-coupled receptor associated sorting protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPRASP1 mRNA

NCBI chr X:98,764,853...98,772,685
Ensembl chr X:98,709,841...98,772,851

G

G protein-coupled receptor associated sorting protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPRASP2 mRNA

NCBI chr X:98,817,668...98,823,814
Ensembl chr X:98,817,593...98,824,402

G

glutathione peroxidase 1

multiple interactions
decreases activity
decreases expression

GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb]
Maneb results in decreased activity of GPX1 protein
[Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA
Maneb results in decreased expression of GPX1 mRNA

PMID:15824117 PMID:26210702 PMID:28322069 PMID:29859004

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 4

increases expression
multiple interactions

Maneb results in increased expression of GPX4 mRNA
[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein
[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]

PMID:23764462 PMID:30797899

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth factor receptor bound protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

glutamate ionotropic receptor delta type subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRID1 mRNA

NCBI chr16:10,138,564...10,885,803
Ensembl chr16:10,138,925...10,885,808

G

glutamate ionotropic receptor kainate type subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRIK2 mRNA

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

G protein-coupled receptor kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRK6 mRNA

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

gasdermin E

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSDME mRNA

NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806

G

glycogen synthase kinase 3 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

G1 to S phase transition 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSPT2 mRNA

NCBI chr X:59,587,237...59,589,758
Ensembl chr X:59,587,276...59,594,162

G

glutathione-disulfide reductase

multiple interactions

[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein

PMID:23159886 PMID:23764462

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 3

increases expression

Maneb results in increased expression of GSTA3 mRNA

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 4

multiple interactions
increases activity
increases expression

[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]
Maneb results in increased activity of GSTA4 protein
Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein

PMID:20888808 PMID:23159886

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase pi 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]

PMID:23963992 PMID:36117858

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

guanylate cyclase 1 soluble subunit alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GUCY1A2 mRNA

NCBI chr 8:500,212...900,201
Ensembl chr 8:500,212...889,203

G

guanylate kinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA

NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107

G

H2A clustered histone 20

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA

NCBI chr 2:183,779,879...183,780,357

G

H2A clustered histone 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of H2AC6 mRNA

NCBI chr17:42,799,884...42,800,387
Ensembl chr17:42,799,652...42,800,381

G

H2A.X variant histone

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 9

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

hyaluronan binding protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HABP4 mRNA

NCBI chr17:934,931...957,604
Ensembl chr17:935,654...957,565

G

hyaluronan and proteoglycan link protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HAPLN1 mRNA

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

hemoglobin alpha, adult chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HBA-A1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA

PMID:18386188 PMID:36117858

NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin alpha, adult chain 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HBA-A2 mRNA

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392

G

histone deacetylase 3

decreases activity

Maneb results in decreased activity of HDAC3 protein

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 6

decreases activity
multiple interactions

Maneb results in decreased activity of HDAC6 protein
[Maneb co-treated with Paraquat] results in decreased expression of HDAC6 mRNA

PMID:21251949 PMID:36117858

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

helicase, POLQ-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HELQ mRNA

NCBI chr14:8,818,582...8,862,926
Ensembl chr14:8,818,592...8,862,960

G

HECT and RLD domain containing E3 ubiquitin protein ligase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HERC3 mRNA

NCBI chr 4:87,952,202...88,042,492
Ensembl chr 4:87,952,274...88,042,488

G

hes family bHLH transcription factor 3

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA

NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261

G

hes-related family bHLH transcription factor with YRPW motif 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA

PMID:23017109 PMID:36117858

NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218

G

hes-related family bHLH transcription factor with YRPW motif-like

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA

NCBI chr 5:135,508,160...135,525,152
Ensembl chr 5:135,508,160...135,525,152

G

HIVEP zinc finger 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HIVEP2 mRNA

NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993

G

hexokinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

HLF transcription factor, PAR bZIP family member

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HLF mRNA

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

high mobility group AT-hook 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

high mobility group nucleosome binding domain 5

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

HMG-box containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HMGXB3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of HMGXB3 mRNA

NCBI chr18:54,590,558...54,638,050
Ensembl chr18:54,590,560...54,638,155

G

heme oxygenase 1

increases expression
multiple interactions

Maneb results in increased expression of HMOX1 protein
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein

PMID:15527874 PMID:23764462

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine N-methyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HNMT mRNA

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA

NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997

G

homer scaffold protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

homer scaffold protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HOMER2 mRNA

NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:135,567,414...135,659,772

G

hook microtubule-tethering protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HOOK1 mRNA

NCBI chr 5:110,824,501...110,887,791
Ensembl chr 5:110,824,501...110,887,787

G

hippocalcin-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HPCAL1 mRNA

NCBI chr 6:40,478,206...40,584,721
Ensembl chr 6:40,478,208...40,584,687

G

hippocalcin-like 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HPCAL4 mRNA

NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416

G

harakiri, BCL2 interacting protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HRK mRNA

NCBI chr12:38,387,484...38,409,652

G

hydroxysteroid 11-beta dehydrogenase 2

decreases activity

Maneb results in decreased activity of HSD11B2 protein

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

heat shock transcription factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class A member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA]

PMID:18386188 PMID:23963992

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA]

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

5-hydroxytryptamine receptor 2C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HTR2C mRNA

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

HUS1 checkpoint clamp component

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HUS1 mRNA

NCBI chr14:83,688,702...83,703,466
Ensembl chr14:83,688,708...83,703,442

G

intercellular adhesion molecule 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

intercellular adhesion molecule 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA]

NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084

G

iduronate 2-sulfatase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IDS mRNA

NCBI chr X:149,025,976...149,046,641
Ensembl chr X:149,025,976...149,046,663

G

immediate early response 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5-like

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of IER5L mRNA

NCBI chr 3:13,744,056...13,745,647
Ensembl chr 3:13,744,078...13,745,647

G

interferon, alpha-inducible protein 27 like 2B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IFI27L2A mRNA

NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360

G

interferon gamma

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

immunoglobin superfamily, member 21

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IGSF21 mRNA

NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174

G

immunoglobulin superfamily, member 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IGSF5 mRNA

NCBI chr11:35,686,513...35,729,396
Ensembl chr11:35,686,705...35,741,129

G

interleukin 1 beta

multiple interactions
increases expression

[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA]
[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of IL1B protein; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]

PMID:23159886 PMID:23963992 PMID:29568078 PMID:32169474 PMID:32375810 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA; [Paraquat co-treated with Maneb] affects the expression of INHBA mRNA

PMID:22563483 PMID:23017109

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

inka box actin regulator 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAM212B mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

inositol polyphosphate-4-phosphatase type I A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of INPP4A mRNA

NCBI chr 9:39,528,245...39,650,574
Ensembl chr 9:39,528,674...39,646,581

G

inositol polyphosphate-4-phosphatase type II B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INPP4B mRNA

NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INPP5D mRNA

NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746

G

insulin induced gene 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

IQ motif and Sec7 domain ArfGEF 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IQSEC3 mRNA

NCBI chr 4:154,610,933...154,707,310
Ensembl chr 4:154,610,934...154,707,310

G

insulin receptor substrate 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA]

PMID:23963992 PMID:36117858

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

immunoglobulin superfamily containing leucine-rich repeat 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ISLR2 mRNA

NCBI chr 8:58,608,165...58,616,246
Ensembl chr 8:58,608,709...58,614,650

G

integrin subunit alpha 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha M

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA]

PMID:28202386 PMID:30797899 PMID:32169474 PMID:32375810

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 8

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:140,127,203...140,208,476

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA]

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

influenza virus NS1A binding protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IVNS1ABP mRNA

NCBI chr13:63,427,040...63,446,701
Ensembl chr13:63,427,041...63,446,701

G

Jupiter microtubule associated homolog 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of JPT1 mRNA

NCBI chr10:100,744,468...100,762,504
Ensembl chr10:100,686,797...100,784,513

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN protein]

PMID:27460631 PMID:33368748

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily A member 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KCNA2 mRNA

NCBI chr 2:194,704,555...194,718,387
Ensembl chr 2:194,704,639...194,718,400

G

potassium voltage-gated channel subfamily A member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNA5 mRNA

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium voltage-gated channel subfamily C member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNC1 mRNA

NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744

G

potassium voltage-gated channel subfamily C member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNC3 mRNA

NCBI chr 1:95,080,960...95,095,165
Ensembl chr 1:95,080,960...95,095,160

G

potassium voltage-gated channel subfamily D member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCND1 mRNA

NCBI chr X:14,661,688...14,678,745
Ensembl chr X:14,662,357...14,677,233

G

potassium voltage-gated channel subfamily D member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCND3 mRNA

NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345

G

potassium voltage-gated channel subfamily H member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KCNH3 mRNA

NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855

G

potassium inwardly-rectifying channel, subfamily J, member 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNJ12 mRNA

NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KCNJ3 mRNA

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium two pore domain channel subfamily K member 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNK12 mRNA

NCBI chr 6:6,740,147...6,790,664
Ensembl chr 6:6,739,991...6,790,661

G

potassium calcium-activated channel subfamily M alpha 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KCNMA1 mRNA

NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNMB4 mRNA

NCBI chr 7:52,066,145...52,119,098
Ensembl chr 7:52,066,136...52,119,278

G

potassium channel tetramerization domain containing 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCTD10 mRNA

NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783

G

KH RNA binding domain containing, signal transduction associated 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KHDRBS2 mRNA

NCBI chr 9:34,447,023...34,953,684
Ensembl chr 9:34,447,056...34,915,530

G

KH RNA binding domain containing, signal transduction associated 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KHDRBS3 mRNA

NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460

G

kinesin family member 1B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KIF1B mRNA

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

kinesin family member 3B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KIF3B mRNA

NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

Maneb results in decreased expression of KIT

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kelch-like family member 15

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KLHL15 mRNA

NCBI chr X:58,994,726...59,050,207
Ensembl chr X:58,995,461...59,046,069

G

kelch-like family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KLHL2 mRNA

NCBI chr16:24,860,744...24,973,348
Ensembl chr16:24,860,667...24,973,341

G

kelch-like family member 32

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KLHL32 mRNA

NCBI chr 5:38,321,237...38,568,453
Ensembl chr 5:38,325,543...38,568,650

G

kelch-like family, member 42

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KLHL42 mRNA

NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:180,004,580...180,027,283

G

KRI1 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KRI1 mRNA

NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392

G

laminin subunit alpha 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit gamma 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

ligand dependent nuclear receptor corepressor-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

lactate dehydrogenase A

increases activity

Maneb results in increased activity of LDHA protein

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

LIF receptor subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LIFR mRNA

NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699

G

LIM domain kinase 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LIMK2 mRNA

NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007

G

lin-7 homolog A, crumbs cell polarity complex component

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LIN7A mRNA

NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550

G

leishmanolysin like peptidase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LMLN mRNA

NCBI chr11:67,656,241...67,725,889
Ensembl chr11:67,658,152...67,724,243

G

LIM domain only 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LMO3 mRNA

NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222

G

loricrin cornified envelope precursor protein

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

lipoprotein lipase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine rich repeat and fibronectin type III domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRFN1 mRNA

NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449

G

leucine rich repeat and fibronectin type III domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRFN5 mRNA

NCBI chr 6:79,466,403...79,822,821
Ensembl chr 6:79,467,961...79,822,815

G

LDL receptor related protein 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LRP4 mRNA

NCBI chr 3:77,429,600...77,483,593
Ensembl chr 3:77,429,798...77,483,593

G

leucine rich repeat containing 17

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LRRC17 mRNA

NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845

G

leucine rich repeat containing 24

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRC24 mRNA

NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438

G

leucine rich repeat containing 41

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LRRC41 mRNA

NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449

G

leucine rich repeat containing 4C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRC4C mRNA

NCBI chr 3:82,305,495...83,684,039
Ensembl chr 3:83,483,851...83,687,774

G

leucine rich repeat containing 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRC7 mRNA

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

leucine-rich repeat kinase 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; [Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]

PMID:23017109 PMID:34897981

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

leucine rich repeat neuronal 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRN2 mRNA

NCBI chr13:44,321,944...44,382,454
Ensembl chr13:44,321,364...44,382,482

G

leucine rich repeat neuronal 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRN3 mRNA

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330

G

leucine rich repeat transmembrane neuronal 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRTM3 mRNA

NCBI chr20:24,515,627...24,689,669
Ensembl chr20:24,515,627...24,689,669

G

LSM11, U7 small nuclear RNA associated

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LSM11 mRNA

NCBI chr10:30,367,841...30,385,956
Ensembl chr10:30,370,727...30,385,944

G

latent transforming growth factor beta binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LTBP1 mRNA

NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349

G

lymphocyte antigen 6 family member A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

Ly6/neurotoxin 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LYNX1 mRNA

NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023

G

Ly6/Plaur domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LYPD1 mRNA

NCBI chr13:37,326,459...37,368,515
Ensembl chr13:37,326,464...37,368,493

G

leucine zipper tumor suppressor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

microtubule-actin crosslinking factor 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MACF1 mRNA

NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905

G

MAP-kinase activating death domain

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MADD mRNA

NCBI chr 3:77,114,330...77,157,865
Ensembl chr 3:77,114,314...77,157,701

G

microtubule-associated protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2K4 mRNA

NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993

G

mitogen-activated protein kinase kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen activated protein kinase kinase kinase 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAP3K7 mRNA

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

microtubule-associated protein 9

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP9 mRNA

NCBI chr 2:167,708,661...167,743,927
Ensembl chr 2:167,708,765...167,740,736

G

mitogen activated protein kinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein]

PMID:15824117 PMID:30797899

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 15

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MAPK15 mRNA

NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645

G

mitogen activated protein kinase 3

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein]

PMID:15824117 PMID:30797899

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAPK8 mRNA

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microtubule-associated protein tau

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

membrane associated ring-CH-type finger 9

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MARCHF9 mRNA

NCBI chr 7:62,879,017...62,882,495
Ensembl chr 7:62,879,018...62,882,495

G

MBL associated serine protease 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MASP1 mRNA

NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974

G

matrilin 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

Mab-21 domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MB21D2 mRNA

NCBI chr11:71,825,748...71,924,770
Ensembl chr11:71,825,748...71,924,769

G

methyl-CpG binding domain protein 3

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA

NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165

G

metallo-beta-lactamase domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MBLAC2 mRNA

NCBI chr 2:11,986,075...12,028,882
Ensembl chr 2:11,986,027...12,030,950

G

muscleblind-like splicing regulator 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of MBNL1 mRNA

NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368

G

membrane bound O-acyltransferase domain containing 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MBOAT2 mRNA

NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485

G

MCF.2 cell line derived transforming sequence-like

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MCF2L mRNA

NCBI chr16:76,507,133...76,652,893
Ensembl chr16:76,507,133...76,652,733

G

MCL1 apoptosis regulator, BCL2 family member

increases expression
multiple interactions

Maneb results in increased expression of MCL1 protein
[Paraquat co-treated with Maneb] results in increased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

minichromosome maintenance complex component 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

multiple C2 and transmembrane domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MCTP1 mRNA

NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833

G

MAM domain containing glycosylphosphatidylinositol anchor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MDGA1 mRNA

NCBI chr20:7,900,327...7,964,309
Ensembl chr20:7,904,358...7,963,471

G

MDM4 regulator of p53

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MDM4 mRNA

NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226

G

malic enzyme 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ME3 mRNA

NCBI chr 1:143,534,024...143,735,551
Ensembl chr 1:143,534,139...143,733,132

G

MTOR associated protein, eak-7 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TLDC1 mRNA

NCBI chr19:47,813,899...47,836,830
Ensembl chr19:47,811,416...47,841,278

G

myocyte enhancer factor 2C

multiple interactions

[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

multiple EGF-like-domains 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MEGF9 mRNA

NCBI chr 5:83,993,565...84,105,622
Ensembl chr 5:83,993,565...84,105,622

G

Meis homeobox 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MEIS3 mRNA

NCBI chr 1:76,861,267...76,872,691
Ensembl chr 1:76,861,924...76,872,691

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MFGE8 mRNA

NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073

G

major facilitator superfamily domain containing 4A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MFSD4A mRNA

NCBI chr13:43,469,488...43,510,467
Ensembl chr13:43,469,488...43,510,467

G

MGAT4 family, member C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MGAT4C mRNA

NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571

G

microsomal glutathione S-transferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MICAL3 mRNA

NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590

G

marker of proliferation Ki-67

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

metallophosphoesterase domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MPPED1 mRNA

NCBI chr 7:114,932,221...115,011,797
Ensembl chr 7:114,944,764...115,011,787

G

mannose receptor, C type 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of MRC1 mRNA

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

mitochondrial ribosomal protein L15

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MRPL15 mRNA

NCBI chr 5:14,729,961...14,741,276
Ensembl chr 5:14,729,979...14,741,276

G

myocardin related transcription factor B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MRTFB mRNA

NCBI chr10:1,116,315...1,278,106
Ensembl chr10:1,116,310...1,277,897

G

microtubule crosslinking factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MTCL1 mRNA

NCBI chr 9:106,305,282...106,441,782
Ensembl chr 9:106,321,098...106,442,203

G

methylenetetrahydrofolate reductase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MTHFR mRNA

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

mechanistic target of rapamycin kinase

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in decreased expression of MTOR mRNA; [Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein]

PMID:22292029 PMID:26884967 PMID:36117858

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 6, oligomeric mucus/gel-forming

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MUC6 mRNA

NCBI chr 1:196,726,678...196,764,842
Ensembl chr 1:196,726,807...196,764,842

G

myeloid-associated differentiation marker-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYADML2 mRNA

NCBI chr10:105,922,557...105,927,867
Ensembl chr10:105,925,947...105,927,575

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYCN mRNA

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

myosin heavy chain 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYH7 mRNA

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin light chain 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MYL9 mRNA

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myosin regulatory light chain interacting protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MYLIP mRNA

NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295

G

N-6 adenine-specific DNA methyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of N6AMT1 mRNA

NCBI chr11:26,584,750...26,597,790
Ensembl chr11:26,584,724...26,608,248

G

N(alpha)-acetyltransferase 25, NatB auxiliary subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAA25 mRNA

NCBI chr12:35,098,256...35,150,498
Ensembl chr12:35,098,075...35,150,467

G

nucleosome assembly protein 1-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

nucleosome assembly protein 1-like 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAP1L3 mRNA

NCBI chr X:88,347,595...88,350,393
Ensembl chr X:88,347,598...88,350,393

G

neurobeachin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NBEA mRNA

NCBI chr 2:139,780,021...140,338,639
Ensembl chr 2:139,780,021...140,340,584

G

neutrophil cytosolic factor 1

multiple interactions

[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Maneb co-treated with Paraquat] results in increased expression of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]

PMID:28202386 PMID:29568078 PMID:32375810 PMID:34052309

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

nuclear receptor coactivator 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NCOA7 mRNA

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

neuron-derived neurotrophic factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NDNF mRNA

NCBI chr 4:94,944,392...94,981,871
Ensembl chr 4:94,944,360...94,981,873

G

norrin cystine knot growth factor NDP

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA

NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934

G

N-deacetylase and N-sulfotransferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NDST3 mRNA

NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584

G

NECAP endocytosis associated 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NECAP1 mRNA

NCBI chr 4:156,103,935...156,119,068
Ensembl chr 4:156,103,988...156,119,068

G

neurofilament medium chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

nuclear envelope integral membrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEMP1 mRNA

NCBI chr 7:63,514,025...63,538,791
Ensembl chr 7:63,479,951...63,534,602

G

neuroepithelial cell transforming 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NET1 mRNA

NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441

G

neuralized E3 ubiquitin protein ligase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEURL1A mRNA

NCBI chr 1:246,066,830...246,152,890
Ensembl chr 1:246,067,100...246,152,903

G

neuronal differentiation 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEUROD1 mRNA

NCBI chr 3:64,359,554...64,363,526
Ensembl chr 3:64,359,395...64,363,649

G

neuronal differentiation 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEUROD2 mRNA

NCBI chr10:83,323,801...83,327,986
Ensembl chr10:83,324,442...83,327,986

G

nuclear factor of activated T-cells 5

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NFAT5 mRNA

NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675

G

NFE2 like bZIP transcription factor 2

increases expression
increases response to substance
multiple interactions

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein
NFE2L2 gene mutant form results in increased susceptibility to Maneb
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]

PMID:21402726 PMID:23764462

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NFIB mRNA

NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479

G

nuclear factor kappa B subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein]

PMID:28202386 PMID:29568078

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NHP2 ribonucleoprotein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NHP2 mRNA

NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545

G

ninein-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NINL mRNA

NCBI chr 3:139,748,353...139,814,683
Ensembl chr 3:139,748,355...139,814,622

G

NIPA-like domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NIPAL3 mRNA

NCBI chr 5:147,687,310...147,725,838
Ensembl chr 5:147,685,288...147,726,351

G

NIPBL, cohesin loading factor

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NIPBL mRNA

NCBI chr 2:57,399,443...57,586,770
Ensembl chr 2:57,399,445...57,565,899

G

neuroligin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NLGN1 mRNA

NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464

G

NLR family, pyrin domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein; [Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]

PMID:32375810 PMID:34052309

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nicotinamide nucleotide adenylyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NMNAT1 mRNA

NCBI chr 5:159,910,242...159,928,201
Ensembl chr 5:159,910,242...159,928,180

G

nicotinamide nucleotide adenylyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NMNAT2 mRNA

NCBI chr13:65,105,950...65,277,350
Ensembl chr13:65,105,950...65,278,484

G

noggin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOG mRNA

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nucleolar protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOL4 mRNA

NCBI chr18:13,932,499...14,294,873
Ensembl chr18:13,932,510...14,296,286

G

nitric oxide synthase 2

multiple interactions
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of NOS2 protein; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA]

PMID:20455021 PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NOVA alternative splicing regulator 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOVA1 mRNA

NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289

G

NADPH oxidase 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

neuropeptide S

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NPS mRNA

NCBI chr 1:190,077,040...190,080,821
Ensembl chr 1:190,077,040...190,080,821

G

NAD(P)H quinone dehydrogenase 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NR2F2 mRNA

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NR4A1 mRNA

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

neuregulin 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

nuclear receptor interacting protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NRIP2 mRNA

NCBI chr 4:161,673,964...161,684,055
Ensembl chr 4:161,639,356...161,684,070

G

neuritin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NRN1 mRNA

NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896

G

neurturin

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NRTN mRNA

NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102

G

netrin 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

netrin 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTN4 mRNA

NCBI chr 7:28,186,611...28,300,390
Ensembl chr 7:28,186,611...28,300,390

G

netrin G1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTNG1 mRNA

NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:197,463,945...197,826,997

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NYAP1 mRNA

NCBI chr12:18,956,192...18,967,624
Ensembl chr12:18,956,268...18,967,543

G

ornithine decarboxylase antizyme 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA]

NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453

G

2-oxoglutarate and iron-dependent oxygenase domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of OGFOD1 mRNA

NCBI chr19:10,945,031...10,974,602
Ensembl chr19:10,946,018...10,975,119

G

one cut homeobox 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ONECUT2 mRNA

NCBI chr18:57,831,647...57,890,884
Ensembl chr18:57,832,111...57,879,629

G

oxysterol binding protein-like 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of OSBPL6 mRNA

NCBI chr 3:61,343,776...61,541,170
Ensembl chr 3:61,343,809...61,537,102

G

pyrimidinergic receptor P2Y4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA]

NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748

G

p21 (RAC1) activated kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PAK6 mRNA

NCBI chr 3:105,638,248...105,674,399
Ensembl chr 3:105,638,653...105,672,975

G

peptidase domain containing associated with muscle regeneration 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PAMR1 mRNA

NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606

G

Parkinsonism associated deglycase

multiple interactions
decreases activity

3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; [Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; Maneb results in decreased activity of and results in increased oxidation of PARK7 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]
Maneb results in decreased activity of PARK7 protein

PMID:34897981 PMID:36842454

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

prostate androgen-regulated mucin-like protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PARM1 mRNA

NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314

G

paired box 5

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA

NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326

G

paired box 6

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

pterin-4 alpha-carbinolamine dehydratase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCBD1 mRNA

NCBI chr20:29,037,545...29,044,322
Ensembl chr20:28,953,864...29,044,292
Ensembl chr20:28,953,864...29,044,292

G

protocadherin 11 X-linked

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDH11X mRNA

NCBI chr X:86,058,348...86,751,078
Ensembl chr X:86,058,394...86,747,036

G

protocadherin 18

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDH18 mRNA

NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883

G

protocadherin 19

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH19 mRNA

NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524

G

protocadherin 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA]

NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051

G

protocadherin 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH9 mRNA

NCBI chr15:69,340,108...70,237,531
Ensembl chr15:69,340,645...70,237,538

G

protocadherin beta 20

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDHB14 mRNA

NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,211,883...29,215,258

G

polycomb group ring finger 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCGF2 mRNA

NCBI chr10:82,682,563...82,694,563
Ensembl chr10:82,683,553...82,693,406

G

PCNA clamp associated factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

proliferating cell nuclear antigen

multiple interactions

3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

Purkinje cell protein 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PCP2 mRNA

NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899

G

programmed cell death 10

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PDCD10 mRNA

NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018

G

phosphodiesterase 10A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE10A mRNA

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563

G

phosphodiesterase 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA]

PMID:23963992 PMID:36117858

NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580

G

phosphodiesterase 2A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE2A mRNA

NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434

G

platelet derived growth factor receptor alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA]

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

pyruvate dehydrogenase E1 subunit alpha 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA]

PMID:23562983 PMID:23963992

NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311

G

prodynorphin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PDYN

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

PDZ domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDZD2 mRNA

NCBI chr 2:61,384,614...61,770,516
Ensembl chr 2:61,386,381...61,770,524

G

PDZ domain containing 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDZD4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDZD4 mRNA

NCBI chr X:151,530,390...151,560,779
Ensembl chr X:151,530,390...151,560,826

G

platelet endothelial aggregation receptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PEAR1 mRNA

NCBI chr 2:173,206,298...173,234,106
Ensembl chr 2:173,207,664...173,227,440

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein]

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

paternally expressed 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PEG10 mRNA

NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621

G

p53 apoptosis effector related to PMP22

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

post-GPI attachment to proteins inositol deacylase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGAP1 mRNA

NCBI chr 9:55,975,574...56,044,325
Ensembl chr 9:55,975,667...56,044,464

G

phosphoglucomutase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGM2 mRNA

NCBI chr14:44,166,314...44,199,828
Ensembl chr14:44,164,425...44,199,967

G

phosphoglucomutase 2-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphatidylglycerophosphate synthase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PGS1 mRNA

NCBI chr10:103,214,635...103,250,254
Ensembl chr10:103,214,646...103,250,254

G

phosphatidylinositol glycan anchor biosynthesis, class C

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PIGC mRNA

NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211

G

phosphatidylinositol glycan anchor biosynthesis, class W

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PIGW mRNA

NCBI chr10:69,746,996...69,782,656
Ensembl chr10:69,748,789...69,790,475

G

phosphoinositide-3-kinase regulatory subunit 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PIK3R3 mRNA

NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583

G

PITPNM family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PITPNM3 mRNA

NCBI chr10:56,674,697...56,766,552
Ensembl chr10:56,676,261...56,766,584

G

cAMP-dependent protein kinase inhibitor beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PKIB mRNA

NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187

G

phospholipase C, epsilon 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PLCE1 mRNA

NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438

G

pleckstrin homology and RUN domain containing M2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLEKHM2 mRNA

NCBI chr 5:153,939,582...153,978,625
Ensembl chr 5:153,940,262...153,978,689

G

phospholipid phosphatase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLPP4 mRNA

NCBI chr 1:183,829,794...183,959,319
Ensembl chr 1:183,830,409...183,959,319

G

plexin A1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLXNA1 mRNA

NCBI chr 4:121,737,934...121,782,901
Ensembl chr 4:121,737,945...122,024,196

G

plexin C1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLXNC1 mRNA

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

Maneb results in increased expression of PMAIP1 mRNA; Maneb results in increased expression of PMAIP1 protein

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

prepronociceptin

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PNOC

NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867

G

RNA polymerase I subunit B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of POLR1B mRNA

NCBI chr 3:116,333,910...116,358,385
Ensembl chr 3:116,333,889...116,358,379

G

RNA polymerase I and III subunit C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of POLR1C mRNA

NCBI chr 9:14,735,740...14,739,852
Ensembl chr 9:14,735,714...14,739,852

G

RNA polymerase II, I and III subunit K

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of POLR2K mRNA

NCBI chr 7:67,347,118...67,359,466
Ensembl chr 7:67,356,113...67,357,668

G

POM121 transmembrane nucleoporin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of POM121 mRNA

NCBI chr12:21,273,713...21,294,299
Ensembl chr12:21,276,913...21,294,294

G

POU class 3 homeobox 3

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA

NCBI chr 9:44,945,872...44,948,998
Ensembl chr 9:44,945,872...44,948,992

G

PTPRF interacting protein alpha 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPFIA3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PPFIA3 mRNA

NCBI chr 1:95,817,110...95,845,950
Ensembl chr 1:95,817,110...95,845,798

G

diphosphoinositol pentakisphosphate kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPIP5K1 mRNA

NCBI chr 3:108,284,120...108,327,683
Ensembl chr 3:108,284,120...108,323,428

G

protein phosphatase 1, regulatory subunit 3F

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP1R3F mRNA

NCBI chr X:14,915,740...14,945,249
Ensembl chr X:14,929,323...14,945,193

G

protein phosphatase 2, regulatory subunit B, gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP2R2C mRNA

NCBI chr14:73,846,547...73,931,489
Ensembl chr14:73,846,547...73,931,864

G

protein phosphatase 6, regulatory subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP6R1 mRNA

NCBI chr 1:69,190,856...69,217,598
Ensembl chr 1:69,189,822...69,216,272

G

peptidylprolyl isomerase domain and WD repeat containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPWD1 mRNA

NCBI chr 2:35,337,301...35,360,661
Ensembl chr 2:35,335,962...35,360,460

G

PR/SET domain 15

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRDM15 mRNA

NCBI chr11:37,164,608...37,225,172
Ensembl chr11:37,165,575...37,222,207

G

peroxiredoxin 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

peroxiredoxin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]

NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA]

PMID:27460631 PMID:33368748

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase C, zeta

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PRKCZ mRNA

NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein

PMID:22563483 PMID:23985028

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

prolactin

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PRL mRNA

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

protein arginine methyltransferase 8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRMT8 mRNA

NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930

G

proline rich 7 (synaptic)

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PRR7 mRNA

NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536

G

proline-rich transmembrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PRRT1 mRNA

NCBI chr20:4,117,957...4,121,643
Ensembl chr20:4,117,957...4,121,600

G

prosaposin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PSAP mRNA

NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498

G

presenilin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

proteasome 20S subunit beta 1

multiple interactions

Maneb inhibits the reaction [Paraquat results in decreased expression of PSMB1 mRNA]

NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560

G

proteasome 26S subunit, ATPase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA

PMID:23963992 PMID:26498265

NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494

G

patched domain containing 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PTCHD4 mRNA

NCBI chr 9:18,462,934...18,666,272
Ensembl chr 9:18,463,737...18,665,705

G

protein tyrosine kinase 2 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form; [Maneb co-treated with Paraquat] results in decreased expression of PTK2B mRNA

PMID:19883720 PMID:36117858

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

protein tyrosine phosphatase, non-receptor type 4

affects activity

Maneb affects the activity of PTPN4 protein

NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170

G

protein tyrosine phosphatase, non-receptor type 9

affects activity

Maneb affects the activity of PTPN9 protein

NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952

G

protein tyrosine phosphatase, receptor type, F

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PTPRF mRNA

NCBI chr 5:131,741,959...131,824,000
Ensembl chr 5:131,742,754...131,810,023

G

protein tyrosine phosphatase, receptor type, O

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PTPRO mRNA

NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771

G

protein tyrosine phosphatase, receptor type, U

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PTPRU mRNA

NCBI chr 5:143,950,542...144,024,791
Ensembl chr 5:143,950,965...144,024,768

G

RAB27A, member RAS oncogene family

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RAB27A mRNA

NCBI chr 8:73,782,730...73,836,630
Ensembl chr 8:73,782,694...73,847,829

G

Rab40b, member RAS oncogene family

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RAB40B mRNA

NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

Ral GTPase activating protein non-catalytic subunit beta

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RALGAPB mRNA

NCBI chr 3:147,062,443...147,152,090
Ensembl chr 3:147,062,364...147,152,090

G

Rap guanine nucleotide exchange factor like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RAPGEFL1 mRNA

NCBI chr10:83,793,711...83,810,373
Ensembl chr10:83,793,694...83,810,371

G

arginyl-tRNA synthetase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RARS mRNA

NCBI chr10:20,270,744...20,295,192
Ensembl chr10:20,270,483...20,295,196

G

RasGEF domain family, member 1A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RASGEF1A mRNA

NCBI chr 4:151,187,533...151,267,982
Ensembl chr 4:151,225,856...151,267,995

G

RAS protein-specific guanine nucleotide-releasing factor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RASGRF2 mRNA

NCBI chr 2:23,113,613...23,361,537
Ensembl chr 2:23,117,004...23,361,240

G

RAS guanyl releasing protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RASGRP1 mRNA

NCBI chr 3:104,168,549...104,230,107
Ensembl chr 3:104,170,013...104,230,056

G

Ras association domain family member 8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RASSF8 mRNA

NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690

G

RB transcriptional corepressor 1

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of RB1 mRNA]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

ring-box 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RBX1 mRNA

NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051

G

regulator of calcineurin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RCAN1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of RCAN1 mRNA

NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein; [Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein]

PMID:28202386 PMID:29568078

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

refilin B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RFLNB mRNA

NCBI chr10:60,893,693...60,899,970
Ensembl chr10:60,893,713...60,899,976

G

regulator of G-protein signaling 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RGS4 mRNA

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

regulator of G-protein signaling 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RGS7 mRNA

NCBI chr13:86,979,269...87,408,834
Ensembl chr13:86,979,279...87,408,888

G

regulating synaptic membrane exocytosis 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RIMS3 mRNA

NCBI chr 5:134,429,092...134,468,935
Ensembl chr 5:134,435,829...134,640,489

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA]

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

Ras-like without CAAX 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RIT2 mRNA

NCBI chr18:22,565,403...22,921,648
Ensembl chr18:22,565,404...22,921,648

G

Rho family GTPase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RND1 mRNA

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

ring finger protein 150

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RNF150 mRNA

NCBI chr19:25,006,978...25,229,273
Ensembl chr19:25,006,611...25,228,678

G

ring finger protein 157

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RNF157 mRNA

NCBI chr10:101,571,972...101,639,874
Ensembl chr10:101,566,295...101,639,942

G

ring finger protein 208

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RNF208 mRNA

NCBI chr 3:8,057,808...8,059,721
Ensembl chr 3:8,043,685...8,059,844

G

ring finger protein 220

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RNF220 mRNA

NCBI chr 5:130,739,173...130,961,386
Ensembl chr 5:130,739,183...130,961,418

G

Rho-associated coiled-coil containing protein kinase 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ROCK1 mRNA

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

RAR-related orphan receptor A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RORA mRNA

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

ribosomal protein L12

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPL12 mRNA

NCBI chr 3:16,264,269...16,266,645
Ensembl chr 3:16,264,251...16,266,642

G

ribosomal protein L19

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA]

NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112

G

ribosomal protein L41

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPL41 mRNA

NCBI chr 7:977,885...978,965

G

ribosomal protein L8

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPL8 mRNA

NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482
Ensembl chr 3:108,622,324...108,628,482

G

ribosomal protein L9

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPL9 mRNA

NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136
Ensembl chr 3:42,893,942...42,897,136

G

reprimo, TP53 dependent G2 arrest mediator homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RPRM mRNA

NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998

G

ribosomal protein S12

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPS12 mRNA

NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014

G

ribosomal protein S15

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPS15 mRNA

NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450

G

ribosomal protein S27

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPS27 mRNA

NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964

G

ribosomal protein S6 kinase A2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of RPS6KA2 mRNA

NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739

G

ribosomal RNA processing 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RRP12 mRNA

NCBI chr 1:240,672,378...240,705,992
Ensembl chr 1:240,672,382...240,706,018

G

reticulon 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of RTN4 mRNA

NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686

G

reticulon 4 receptor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of RTN4R mRNA

NCBI chr11:82,844,309...82,869,251
Ensembl chr11:82,844,309...82,869,466

G

reticulon 4 receptor-like 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of RTN4RL2 mRNA

NCBI chr 3:69,954,557...69,971,108
Ensembl chr 3:69,955,169...69,971,488

G

S100 calcium binding protein A8

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

sacsin molecular chaperone

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SACS mRNA

NCBI chr15:35,285,783...35,370,335
Ensembl chr15:35,285,782...35,370,335

G

sterile alpha motif domain containing 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SAMD10 mRNA

NCBI chr 3:168,700,280...168,704,427
Ensembl chr 3:168,700,284...168,705,248

G

sterile alpha motif domain containing 14

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SAMD14 mRNA

NCBI chr10:79,957,111...79,972,347
Ensembl chr10:79,957,758...79,972,341

G

sterile alpha motif domain containing 4A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SAMD4 mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

secretory carrier membrane protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA]

NCBI chr 8:57,965,612...57,992,248
Ensembl chr 8:57,965,631...57,992,646

G

SCAN domain-containing 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of SCAND1 mRNA

NCBI chr 3:144,818,615...144,819,479
Ensembl chr 3:144,818,611...144,820,025

G

sodium voltage-gated channel alpha subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SCN2A mRNA

NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214

G

sodium voltage-gated channel beta subunit 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SCN3B mRNA

NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868

G

succinate dehydrogenase complex iron sulfur subunit B

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of SDHB mRNA

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

semaphorin 3E

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SEMA3E mRNA

NCBI chr 4:20,297,534...20,555,287
Ensembl chr 4:20,299,718...20,555,229

G

semaphorin 4D

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA

NCBI chr17:13,430,324...13,537,146
Ensembl chr17:13,430,379...13,537,138

G

semaphorin 5A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SEMA5A mRNA

NCBI chr 2:83,309,843...83,741,084
Ensembl chr 2:83,309,843...83,741,084

G

semaphorin 6B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SEMA6B mRNA

NCBI chr 9:950,939...967,905
Ensembl chr 9:950,939...961,521

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SERP2 mRNA

NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785

G

SET domain containing 6, protein lysine methyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

sideroflexin 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

small G protein signaling modulator 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SGSM1 mRNA

NCBI chr12:43,320,500...43,386,469
Ensembl chr12:43,321,256...43,386,457

G

small G protein signaling modulator 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SGSM2 mRNA

NCBI chr10:59,718,180...59,759,822
Ensembl chr10:59,718,183...59,759,447

G

small G protein signaling modulator 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SGSM3 mRNA

NCBI chr 7:112,514,453...112,544,109
Ensembl chr 7:112,514,630...112,544,108

G

small glutamine rich tetratricopeptide repeat co-chaperone beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SGTB mRNA; [Maneb co-treated with Paraquat] results in increased expression of SGTB mRNA

NCBI chr 2:35,233,045...35,269,527
Ensembl chr 2:35,233,042...35,269,518

G

SH3 domain containing ring finger 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SH3RF1 mRNA

NCBI chr16:28,735,522...28,901,261
Ensembl chr16:28,735,440...28,901,644

G

SH3 and SYLF domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SH3YL1 mRNA

NCBI chr 6:47,522,098...47,565,858
Ensembl chr 6:47,522,091...47,565,858

G

shisa family member 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SHISA7 mRNA

NCBI chr 1:68,993,900...69,012,943
Ensembl chr 1:68,994,025...69,012,943

G

shisa family member 9

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SHISA9 mRNA

NCBI chr10:3,335,616...3,629,334
Ensembl chr10:3,337,979...3,627,773

G

shootin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SHTN1 mRNA

NCBI chr 1:258,121,966...258,225,861
Ensembl chr 1:258,121,968...258,228,265

G

signal-induced proliferation-associated 1 like 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SIPA1L3 mRNA

NCBI chr 1:84,618,714...84,825,956
Ensembl chr 1:84,618,719...84,703,802

G

sirtuin 1

decreases activity

Maneb results in decreased activity of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

decreases activity

Maneb results in decreased activity of SIRT2 protein

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

decreases activity

Maneb results in decreased activity of SIRT3 protein

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

S-phase kinase associated protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SKP2 mRNA

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 12 member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC12A2 mRNA

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 17 member 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC17A6 mRNA

NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542

G

solute carrier family 17 member 8

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of SLC17A8 mRNA

NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079

G

solute carrier family 18 member A2

multiple interactions
decreases expression

[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA; Ketoconazole inhibits the reaction [Maneb results in decreased expression of SLC18A2 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]

PMID:18386188 PMID:20964710 PMID:22334051

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 1 member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC1A5 mRNA

NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952

G

solute carrier family 22 member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 25, member 42

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025

G

solute carrier family 25, member 53

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC25A53 mRNA

NCBI chr X:100,306,917...100,319,662
Ensembl chr X:100,306,915...100,319,863

G

solute carrier family 2 member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 36 member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC36A4 mRNA

NCBI chr 8:12,519,613...12,552,671
Ensembl chr 8:12,519,943...12,552,031

G

solute carrier family 39 member 14

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC39A14 mRNA

NCBI chr15:45,376,806...45,423,549
Ensembl chr15:45,376,917...45,423,524

G

solute carrier family 39 member 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC39A6 mRNA

NCBI chr18:15,864,874...15,885,417
Ensembl chr18:15,864,875...15,885,417

G

solute carrier family 40 member 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein]

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

solute carrier family 5 member 7

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of SLC5A7 mRNA

NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258

G

solute carrier family 6 member 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions
affects response to substance

[Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 protein
SLC6A3 gene polymorphism affects the susceptibility to Maneb

PMID:11124998 PMID:18386188 PMID:19590691

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 7 member 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SLC7A1 mRNA

NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849

G

solute carrier family 7 member 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC7A6 mRNA

NCBI chr19:34,073,472...34,100,268
Ensembl chr19:34,074,286...34,100,268

G

solute carrier family 8 member A1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

solute carrier family 8 member A3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC8A3 mRNA

NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508

G

solute carrier family 9 member A8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLC9A8 mRNA

NCBI chr 3:156,147,855...156,198,497
Ensembl chr 3:156,148,104...156,198,471

G

SMC5-SMC6 complex localization factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLF1 mRNA

NCBI chr 2:6,767,015...6,874,428
Ensembl chr 2:6,767,015...6,867,149

G

schlafen family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SLFN2 mRNA

NCBI chr10:67,953,322...67,959,659
Ensembl chr10:67,953,171...67,959,458

G

SLIT and NTRK-like family, member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLITRK4 mRNA

NCBI chr X:142,706,495...142,718,968
Ensembl chr X:142,706,338...142,718,575

G

SLIT and NTRK-like family, member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SLITRK5 mRNA

NCBI chr15:88,848,123...88,858,809
Ensembl chr15:88,847,535...88,856,836

G

small integral membrane protein 13

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SMIM13 mRNA

NCBI chr17:23,497,662...23,515,705

G

SPARC related modular calcium binding 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SMOC2 mRNA

NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693

G

synuclein alpha

multiple interactions
increases response to substance

[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein; [Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]; [Paraquat co-treated with Maneb] results in increased expression of SNCA protein; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]
SNCA gene mutant form results in increased susceptibility to Maneb
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein; Maneb promotes the reaction [Paraquat results in increased expression of SNCA protein]; Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]; Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Maneb]; SNCA protein results in increased susceptibility to [Maneb co-treated with Paraquat]

PMID:23017109 PMID:24290359 PMID:26498265 PMID:27324791 PMID:29568078 More...

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

sorting nexin 19

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SNX19 mRNA

NCBI chr 8:28,829,881...28,867,600
Ensembl chr 8:28,829,886...28,867,061

G

suppressor of cytokine signaling 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

superoxide dismutase 1

multiple interactions

SOD1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb]
[Maneb co-treated with Paraquat] results in increased expression of SOD1 mRNA
[Paraquat co-treated with Maneb] results in decreased expression of SOD1 mRNA

PMID:15824117 PMID:18386188 PMID:29859004

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
decreases expression

[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]
Maneb results in decreased expression of SOD2 mRNA

PMID:23562983 PMID:26210702

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin-related VPS10 domain containing receptor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SORCS3 mRNA

NCBI chr 1:247,099,178...247,734,027
Ensembl chr 1:247,099,408...247,734,027

G

sosondowah ankyrin repeat domain family member A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SOWAHA mRNA

NCBI chr10:37,641,823...37,645,390
Ensembl chr10:37,643,444...37,645,102

G

SRY-box transcription factor 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SOX12 mRNA

NCBI chr 3:140,859,499...140,860,518
Ensembl chr 3:140,856,579...140,860,975

G

spermatogenesis associated, serine-rich 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SPATS2 mRNA

NCBI chr 7:130,280,100...130,353,425
Ensembl chr 7:130,280,108...130,353,424

G

serine peptidase inhibitor, Kunitz type, 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SPINT2 mRNA

NCBI chr 1:84,558,159...84,580,616
Ensembl chr 1:84,558,166...84,580,616

G

secreted phosphoprotein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

spectrin, beta, non-erythrocytic 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SPTBN2 mRNA

NCBI chr 1:202,002,970...202,045,343
Ensembl chr 1:202,002,970...202,044,283

G

serine/arginine repetitive matrix 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SRRM4 mRNA

NCBI chr12:39,998,975...40,158,897
Ensembl chr12:39,999,488...40,155,725

G

SS18L1 subunit of BAF chromatin remodeling complex

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SS18L1 mRNA

NCBI chr 3:167,143,730...167,165,253
Ensembl chr 3:167,143,994...167,165,253

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ST6GALNAC5 mRNA

NCBI chr 2:241,741,933...241,911,214
Ensembl chr 2:241,742,688...241,911,208

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ST8SIA5 mRNA

NCBI chr18:70,736,395...70,802,537
Ensembl chr18:70,736,602...70,797,789

G

signal transducer and activator of transcription 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]

NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540

G

stathmin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

stonin 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of STON2 mRNA

NCBI chr 6:110,567,485...110,676,376
Ensembl chr 6:110,567,485...110,676,376

G

spermatid perinuclear RNA binding protein

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of STRBP mRNA

NCBI chr 3:21,328,310...21,467,753
Ensembl chr 3:21,337,855...21,414,949

G

syntaxin 1A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of STX1A mRNA

NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930

G

syntaxin binding protein 5L

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of STXBP5L mRNA

NCBI chr11:63,334,667...63,654,270
Ensembl chr11:63,334,667...63,657,014

G

small ubiquitin-like modifier 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of SUMO1 mRNA

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

synaptic vesicle glycoprotein 2b

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SV2B mRNA

NCBI chr 1:128,978,471...129,152,479
Ensembl chr 1:128,978,473...129,152,479

G

synaptojanin 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SYNJ2 mRNA

NCBI chr 1:46,518,594...46,621,919
Ensembl chr 1:46,518,709...46,633,687

G

synaptotagmin 13

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SYT13 mRNA

NCBI chr 3:78,877,114...78,917,527
Ensembl chr 3:78,877,114...78,917,392

G

synaptotagmin 16

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SYT16 mRNA

NCBI chr 6:92,721,415...92,972,140
Ensembl chr 6:92,721,101...92,971,748

G

synaptotagmin 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]

NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067

G

tachykinin, precursor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TAC1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of TAC1 mRNA

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

TAFA chemokine like family member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM19A5 mRNA

NCBI chr 7:118,613,731...118,835,016
Ensembl chr 7:118,613,889...118,834,353

G

transporter 1, ATP binding cassette subfamily B member

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

TBC1 domain family member 9

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TBC1D9 mRNA

NCBI chr19:24,842,166...24,951,383
Ensembl chr19:24,842,205...24,943,129

G

TBC1 domain containing kinase

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of TBCK mRNA

NCBI chr 2:221,175,749...221,348,058
Ensembl chr 2:221,175,785...221,348,126

G

T-box brain transcription factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TBR1 mRNA

NCBI chr 3:46,350,237...46,368,397
Ensembl chr 3:46,351,213...46,361,041

G

thromboxane A2 receptor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TBXA2R mRNA

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

G

transcription elongation factor A like 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TCEAL3 mRNA

NCBI chr X:100,010,677...100,012,637
Ensembl chr X:100,010,690...100,012,654

G

transcription factor 20

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TCF20 mRNA

NCBI chr 7:113,953,449...114,104,166
Ensembl chr 7:113,954,089...114,051,839

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of TECR mRNA

NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168

G

teneurin transmembrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TENM1 mRNA

NCBI chr X:121,400,466...122,289,877
Ensembl chr X:121,403,649...122,290,207

G

tuftelin interacting protein 11

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TFIP11 mRNA

NCBI chr12:44,299,619...44,311,851
Ensembl chr12:44,299,622...44,311,855

G

transforming growth factor, beta 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TGFB3 mRNA

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

tyrosine hydroxylase

multiple interactions
decreases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; [Paraquat co-treated with Maneb] results in decreased expression of TH protein; [Paraquat co-treated with Maneb] results in increased expression of TH protein; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]
[Paraquat co-treated with Maneb] results in decreased expression of TH; [Paraquat co-treated with Maneb] results in decreased expression of TH mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TH protein

PMID:11124998 PMID:18386188 PMID:20455021 PMID:20964710 PMID:22334051 More...

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

thioesterase superfamily member 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

thyroid hormone receptor beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of THRB mRNA

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

translocase of inner mitochondrial membrane 13

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of TIMM13 mRNA

NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910

G

TLC domain containing 3B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAM57B mRNA

NCBI chr 1:181,421,104...181,439,744
Ensembl chr 1:181,422,830...181,439,743

G

transmembrane channel-like 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMC4 mRNA

NCBI chr 1:65,539,777...65,551,683
Ensembl chr 1:65,539,721...65,551,677

G

transmembrane protein 132A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMEM132A mRNA

NCBI chr 1:207,507,074...207,518,756
Ensembl chr 1:207,507,077...207,518,758

G

transmembrane protein 150C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMEM150C mRNA

NCBI chr14:9,454,999...9,525,300
Ensembl chr14:9,508,515...9,525,298

G

transmembrane protein 151B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMEM151B mRNA

NCBI chr 9:15,456,446...15,464,289
Ensembl chr 9:15,455,801...15,464,302

G

transmembrane protein 38a

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TMEM38A mRNA

NCBI chr16:17,258,160...17,274,204
Ensembl chr16:17,258,164...17,273,415

G

transmembrane protein 42

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of TMEM42 mRNA

NCBI chr 8:122,674,793...122,677,290
Ensembl chr 8:122,674,070...122,677,276

G

transmembrane protein 87A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMEM87A mRNA

NCBI chr 3:107,307,726...107,353,571
Ensembl chr 3:107,307,726...107,353,551

G

transmembrane protein 8B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TMEM8B mRNA

NCBI chr 5:57,919,473...57,948,419
Ensembl chr 5:57,919,804...57,946,772

G

tumor necrosis factor

increases expression
multiple interactions

Maneb results in increased expression of TNF mRNA
[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA; [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]
[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of TNF mRNA]

PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 21

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TNFRSF21 mRNA

NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085

G

tyrosine kinase, non-receptor, 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TNK2 mRNA

NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009

G

tenascin R

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TNR mRNA

PMID:23017109 PMID:36117858

NCBI chr13:71,751,714...72,172,731
Ensembl chr13:72,091,585...72,167,641

G

tumor protein p53

multiple interactions

3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TRP53 protein]; [Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein; [Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form; [Paraquat co-treated with Maneb] results in increased expression of TRP53 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]

PMID:20964710 PMID:23963992 PMID:23985028

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRP53BP1 mRNA

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

G

Traf3 interacting protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ACT1 protein

NCBI chr20:43,011,405...43,054,654
Ensembl chr20:43,011,450...43,054,667

G

TNF receptor associated factor 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

translocation associated membrane protein 1-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRAM1L1 mRNA

NCBI chr 2:212,511,130...212,513,311

G

tripartite motif-containing 32

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRIM32 mRNA

NCBI chr 5:79,005,139...79,016,615
Ensembl chr 5:78,999,389...79,022,018

G

tRNA methyltransferase 61A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRMT61A mRNA

NCBI chr 6:130,737,230...130,743,251
Ensembl chr 6:130,737,219...130,743,243

G

trophinin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRO mRNA

NCBI chr X:19,563,395...19,574,507
Ensembl chr X:19,563,517...19,572,953

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRPC3 mRNA

NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855

G

transient receptor potential cation channel, subfamily C, member 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TRPC4 mRNA

NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768

G

transient receptor potential cation channel, subfamily M, member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TRPM3 mRNA; [Paraquat co-treated with Maneb] affects the expression of TRPM3 mRNA

PMID:22563483 PMID:36117858

NCBI chr 1:219,673,200...220,557,610
Ensembl chr 1:219,672,892...220,560,717

G

tetraspanin 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TSPAN5 mRNA

NCBI chr 2:227,294,180...227,469,361
Ensembl chr 2:227,294,217...227,465,664

G

TSPO associated protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TSPOAP1 mRNA

NCBI chr10:72,554,220...72,586,402
Ensembl chr10:72,560,980...72,586,412

G

TSPY-like 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TSPYL5 mRNA

NCBI chr 7:64,881,504...64,885,512
Ensembl chr 7:64,884,225...64,885,457

G

tetratricopeptide repeat domain 27

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TTC27 mRNA

NCBI chr 6:20,558,756...20,702,126
Ensembl chr 6:20,558,756...20,702,115

G

tweety family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TTYH3 mRNA

NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459

G

tubulin, alpha 1A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, alpha 1B

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of TUBA1B mRNA

NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 5 class I

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA]

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

tumor suppressor candidate 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of TUSC1 mRNA

NCBI chr 5:108,089,952...108,091,315
Ensembl chr 5:108,090,613...108,091,224

G

thioredoxin 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

TYRO3 protein tyrosine kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TYRO3 mRNA

NCBI chr 3:106,777,686...106,797,154
Ensembl chr 3:106,777,635...106,797,142

G

ubiquitin-like modifier activating enzyme 1

multiple interactions

Maneb results in decreased activity of and results in decreased ubiquitination of UBA1 protein

NCBI chr X:1,508,700...1,530,677
Ensembl chr X:1,508,666...1,530,636

G

ubiquitin B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]

NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333

G

ubiquitin C

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

ubiquitin conjugating enzyme E2 V1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UBE2V1 mRNA

NCBI chr 3:156,317,339...156,340,198
Ensembl chr 3:156,316,781...156,340,273

G

upstream binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UBP1 mRNA

NCBI chr 8:113,869,771...113,915,625
Ensembl chr 8:113,869,979...113,915,625

G

ubiquitin protein ligase E3 component n-recognin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UBR3 mRNA

NCBI chr 3:54,649,803...54,806,779
Ensembl chr 3:54,649,992...54,806,247

G

UBX domain protein 7

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of UBXN7 mRNA

NCBI chr11:68,427,896...68,460,100

G

ubiquitin C-terminal hydrolase L1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UCHL1 protein; [Paraquat co-treated with Maneb] results in decreased expression of UCHL1 mRNA

PMID:18386188 PMID:23562983

NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590

G

ubiquitin C-terminal hydrolase L5

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of UCHL5 mRNA

NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502

G

UEV and lactate/malate dehyrogenase domains

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of UEVLD mRNA

NCBI chr 1:97,454,188...97,486,004
Ensembl chr 1:97,453,946...97,486,000

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

unc-13 homolog C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UNC13C mRNA; [Paraquat co-treated with Maneb] affects the expression of UNC13C mRNA

PMID:22563483 PMID:36117858

NCBI chr 8:74,247,026...74,697,629
Ensembl chr 8:74,247,899...74,673,223

G

unc-5 netrin receptor D

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of UNC5D mRNA

NCBI chr16:62,860,119...63,406,932
Ensembl chr16:62,860,174...63,401,143

G

UPF3B, regulator of nonsense mediated mRNA decay

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of UPF3B mRNA

NCBI chr X:116,335,308...116,353,332
Ensembl chr X:116,335,308...116,353,236

G

ubiquinol-cytochrome c reductase core protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]

NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480

G

URB1 ribosome biogenesis homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of URB1 mRNA

NCBI chr11:30,004,539...30,065,315
Ensembl chr11:30,004,539...30,065,363

G

ubiquitin specific peptidase 13

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of USP13 mRNA

NCBI chr 2:115,576,912...115,689,153
Ensembl chr 2:115,577,091...115,686,222

G

ubiquitin specific peptidase 28

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of USP28 mRNA

NCBI chr 8:49,325,766...49,386,229
Ensembl chr 8:49,325,867...49,386,229

G

ubiquitin specific peptidase 29

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of USP29 mRNA

NCBI chr 1:66,874,216...67,097,731
Ensembl chr 1:66,874,017...67,097,686

G

ubiquitin specific peptidase 35

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of USP35 mRNA

NCBI chr 1:151,626,195...151,649,926
Ensembl chr 1:151,626,196...151,650,015

G

vesicle-associated membrane protein 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]

NCBI chr 4:104,423,813...104,435,059
Ensembl chr 4:104,423,820...104,426,212

G

valosin containing protein lysine methyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VCPKMT mRNA

NCBI chr 6:88,036,485...88,042,151
Ensembl chr 6:88,036,494...88,042,000

G

vascular endothelial growth factor A

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VEGFC mRNA

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

vacuolar protein sorting 13 homolog B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VPS13B mRNA

NCBI chr 7:66,557,862...67,128,429
Ensembl chr 7:66,558,471...67,128,429

G

VPS37D subunit of ESCRT-I

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VPS37D mRNA

NCBI chr12:21,609,210...21,614,669
Ensembl chr12:21,609,182...21,614,659

G

vacuolar protein sorting 45 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA]

NCBI chr 2:183,555,919...183,616,312
Ensembl chr 2:183,555,921...183,616,295

G

von Willebrand factor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of VWF mRNA

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

WASP family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of WASF3 mRNA

NCBI chr12:8,563,805...8,660,799
Ensembl chr12:8,562,062...8,660,751

G

WEE1 G2 checkpoint kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

WAP four-disulfide core domain 18

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WFDC18 mRNA

NCBI chr10:68,588,818...68,590,972
Ensembl chr10:68,588,818...68,589,671

G

wolframin ER transmembrane glycoprotein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WFS1 mRNA

NCBI chr14:73,810,478...73,834,993
Ensembl chr14:73,810,404...73,835,602

G

WNK lysine deficient protein kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WNK2 mRNA

NCBI chr17:15,503,672...15,612,479
Ensembl chr17:15,504,261...15,612,479

G

WNK lysine deficient protein kinase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WNK3 mRNA

NCBI chr X:20,156,260...20,299,252
Ensembl chr X:20,157,041...20,296,821

G

Wnt family member 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of WNT1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of WNT1 protein

NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651

G

Wnt family member 5A

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of WNT5A mRNA; [Paraquat co-treated with Maneb] results in increased expression of WNT5A protein

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

Wnt family member 7B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of WNT7B mRNA

NCBI chr 7:116,634,817...116,679,459
Ensembl chr 7:116,634,814...116,679,581

G

xylosyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of XYLT1 mRNA

NCBI chr 1:171,643,925...171,929,774
Ensembl chr 1:171,643,925...171,926,783

G

YjeF N-terminal domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of YJEFN3 mRNA

NCBI chr16:19,533,742...19,539,759
Ensembl chr16:19,533,788...19,539,728

G

zinc finger and BTB domain containing 11

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZBTB11 mRNA

NCBI chr11:44,598,694...44,652,559
Ensembl chr11:44,616,289...44,651,050

G

zinc finger and BTB domain containing 40

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZBTB40 mRNA

NCBI chr 5:149,216,496...149,283,746
Ensembl chr 5:149,219,677...149,254,415

G

zinc finger and BTB domain containing 44

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ZBTB44 mRNA

NCBI chr 8:29,466,055...29,524,027
Ensembl chr 8:29,466,352...29,518,163

G

zinc finger CCHC-type containing 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZCCHC12 mRNA

NCBI chr X:115,433,444...115,436,691
Ensembl chr X:115,433,259...115,436,692

G

zinc finger, DBF-type containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZDBF2 mRNA

NCBI chr 9:64,672,974...64,748,446
Ensembl chr 9:64,709,880...64,744,265

G

zinc finger DHHC-type palmitoyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZDHHC2 mRNA

NCBI chr16:51,808,465...51,878,060
Ensembl chr16:51,808,468...51,878,060

G

zinc finger DHHC-type palmitoyltransferase 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZDHHC5 mRNA

NCBI chr 3:69,772,037...69,800,142
Ensembl chr 3:69,771,890...69,799,921

G

zinc finger protein 131

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZFP131 mRNA; [Maneb co-treated with Paraquat] results in increased expression of ZFP131 mRNA

NCBI chr 2:51,722,774...51,753,662
Ensembl chr 2:51,725,541...51,753,639

G

zinc finger protein 286A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZFP286 mRNA

NCBI chr10:47,450,469...47,461,267
Ensembl chr10:47,450,469...47,463,258

G

zinc finger protein 287

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZFP287 mRNA

NCBI chr10:47,395,650...47,415,610
Ensembl chr10:47,397,285...47,439,755

G

zinc finger protein 346

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZFP346 mRNA

NCBI chr17:9,493,787...9,523,681
Ensembl chr17:9,493,803...9,523,635

G

zinc finger protein 580

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ZFP580 mRNA

NCBI chr 1:68,787,118...68,789,286
Ensembl chr 1:68,787,118...68,789,286

G

zinc finger FYVE-type containing 28

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ZFYVE28 mRNA

NCBI chr14:76,468,424...76,554,039
Ensembl chr14:76,468,424...76,554,039

G

zinc fingers and homeoboxes 3

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ZHX3 mRNA

NCBI chr 3:149,417,787...149,548,671
Ensembl chr 3:149,417,818...149,527,079

Mebhydrolin napadisilate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

diazoline results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

Meglumine sodium amidotrizoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

endothelin 1

increases expression

urovision results in increased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

metiram

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCB1 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCC1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCC1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCC2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCC2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 2

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCG2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCG2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCG2 protein

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

BCL2 associated X, apoptosis regulator

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BAX protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BAX protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BBC3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BBC3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of BCL2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 2

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BIRC2 mRNA

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

caspase 3

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of CASP3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of CASP3 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CASP3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CASP8 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cytochrome c, somatic

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CYCS mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CYCS mRNA

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

glutathione S-transferase mu 1

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of GSTM1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of GSTM1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

histone deacetylase 3

decreases activity

polymarcine results in decreased activity of HDAC3 protein

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 6

decreases activity

polymarcine results in decreased activity of HDAC6 protein

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

major vault protein

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of MVP mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of MVP mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of MVP mRNA

NCBI chr 1:181,594,734...181,622,336
Ensembl chr 1:181,594,734...181,622,380

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

sirtuin 1

decreases activity

polymarcine results in decreased activity of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

decreases activity

polymarcine results in decreased activity of SIRT2 protein

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

decreases activity

polymarcine results in decreased activity of SIRT3 protein

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 5 member 5

multiple interactions

polymarcine inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine]

NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697

G

tumor necrosis factor

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 10b

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of TNFRSF10A mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TNFRSF10A mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

tumor protein p53

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of TP53 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of TP53 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

X-linked inhibitor of apoptosis

multiple interactions

[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

tyloxapol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

tyloxapol results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

albumin

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [tyloxapol results in decreased expression of ALB mRNA]; ferulic acid inhibits the reaction [tyloxapol results in decreased expression of ALB mRNA]; naringenin inhibits the reaction [tyloxapol results in decreased expression of ALB mRNA]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

autophagy related 5

multiple interactions
decreases expression

Escin inhibits the reaction [tyloxapol results in decreased expression of ATG5 protein]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions
decreases expression

Escin inhibits the reaction [tyloxapol results in decreased expression of ATG7 protein]; Fenofibrate inhibits the reaction [tyloxapol results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

butyrylcholinesterase

increases activity

tyloxapol results in increased activity of BCHE protein

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

beclin 1

decreases expression
multiple interactions

tyloxapol results in decreased expression of BECN1 protein
Escin inhibits the reaction [tyloxapol results in decreased expression of BECN1 protein]; Fenofibrate inhibits the reaction [tyloxapol results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

glutamate-cysteine ligase, catalytic subunit

decreases expression
multiple interactions

tyloxapol results in decreased expression of GCLC protein
Escin inhibits the reaction [tyloxapol results in decreased expression of GCLC protein]; Fenofibrate inhibits the reaction [tyloxapol results in decreased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamic--pyruvic transaminase

multiple interactions
increases expression

Escin inhibits the reaction [tyloxapol results in increased expression of GPT protein]; Fenofibrate inhibits the reaction [tyloxapol results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione-disulfide reductase

decreases activity

tyloxapol results in decreased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

interleukin 6

multiple interactions
increases expression

Fenofibrate inhibits the reaction [tyloxapol results in increased expression of IL6 mRNA]; ferulic acid inhibits the reaction [tyloxapol results in increased expression of IL6 mRNA]; naringenin inhibits the reaction [tyloxapol results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Kelch-like ECH-associated protein 1

increases expression
multiple interactions

tyloxapol results in increased expression of KEAP1 protein
Escin inhibits the reaction [tyloxapol results in increased expression of KEAP1 protein]; Fenofibrate inhibits the reaction [tyloxapol results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases lipidation

Escin inhibits the reaction [tyloxapol results in increased lipidation of MAP1LC3B protein]; Fenofibrate inhibits the reaction [tyloxapol results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

paraoxonase 1

decreases activity

tyloxapol results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

decreases expression
multiple interactions

tyloxapol results in decreased expression of PPARA protein
Escin inhibits the reaction [tyloxapol results in decreased expression of PPARA protein]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

sequestosome 1

increases expression
multiple interactions

tyloxapol results in increased expression of SQSTM1 protein
Escin inhibits the reaction [tyloxapol results in increased expression of SQSTM1 protein]; Fenofibrate inhibits the reaction [tyloxapol results in increased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions

tyloxapol results in increased expression of SREBF1 protein
Escin inhibits the reaction [tyloxapol results in increased expression of SREBF1 protein]; Fenofibrate inhibits the reaction [tyloxapol results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

increases expression
multiple interactions

tyloxapol results in increased expression of TNF mRNA
ferulic acid inhibits the reaction [tyloxapol results in increased expression of TNF mRNA]; naringenin inhibits the reaction [tyloxapol results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions
increases expression

ferulic acid inhibits the reaction [tyloxapol results in increased expression of VEGFA mRNA]; naringenin inhibits the reaction [tyloxapol results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19811
chemical entity	19840
chemical substance	14383
mixture	13700
polymer	1026
((R)-3-Hydroxybutanoyl)(n-2)	0
(1->3)-beta-D-Galactopyranans	0
(ribonucleotide)n+m	0
1,3-beta-D-Oligoglucan	0
1,3-beta-D-Xylan	0
1,6-alpha-D-mannosyloligosaccharide	0
10-formyltetrahydrofolyl polyglutamate polymer	0
2-Polyprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone	0
2-Polyprenyl-6-hydroxyphenol	0
2-Polyprenyl-6-methoxyphenol	0
2-polyprenylphenol +	0
3-Polyprenyl-4-hydroxy-5-methoxybenzoate	0
4,4'-Diaminostilbene dihydrochloride	0
4,4'-Stilbenedicarboxamidine dihydrochloride	0
4-poly[(1''->2')-ADP-alpha-D-ribose]-L-aspartate residue	0
5-Hydroxy-2-polyprenylphenol	0
5-Oxoprolyl-tRNA	0
5-methyltetrahydrofolyl polyglutamate polymer	0
5-oxoprolyl-peptide	0
5-poly[(1''->2')-ADP-alpha-D-ribose]-L-glutamate residue	0
5S-rRNA precursor	0
Alkylated DNA	0
Aluminoparaaminosalicylate calcium	0
Amrinone lactate	0
Calcium arsenate	2
Calcium pantothenate	0
Clocapramine dihydrochloride	0
Collagen	1
Cycloguanil pamoate	0
DNA 2,6-diamino-5-formamido-3,4-dihydro-4-oxopyrimidine	0
DNA 4,6-diamino-5-formamidopyrimidine	0
DNA 5-methylcytosine	0
DNA 6-methylaminopurine	0
DNA N(4)-methylcytosine	0
DNA adenine	0
DNA containing 6-O-methylguanine	0
DNA containing guanine	0
DNA cytosine	0
Dimethylaminoethyl reserpilinate dihydrochloride	0
Ferric gluconate	0
Glucosylated DNA	0
HR1917	0
Hexadimethrine bromide	8
Iminoctadine acetate	0
Isomaltosaccharide	0
Kad 1229	0
L-Lysyl-tRNA(Pyl)	0
L-Pyrrolysyl-tRNA(Pyl)	0
L-arginyl-protein	0
L-glutaminyl-peptide	0
L-leucyl-protein	0
L-methionylaminoacyl-tRNA	0
Lactitol dihydrate	0
Laureth 4	0
Linear DNA duplexes	0
Mebhydrolin napadisilate	1
Meglumine sodium amidotrizoate	1
N-Substituted aminoacyl-tRNA	0
N-formyl-L-methionylaminoacyl-tRNA	0
Nonoxynol-9 iodine	0
Nylon 6	0
O-Methylated RNA	0
O-Phosphoseryl-tRNA(Cys)	0
O-Phosphoseryl-tRNA(Sec)	0
Oligoribonucleotide	0
Oligosaccharides with 4-deoxy-alpha-D-gluc-4-enuronosyl group	0
Oligosaccharides with terminal 4-deoxy-6-methyl-alpha-D-galact-4-enuronosyl groups	0
Oligouronides	0
Oxyquinoline sulfate	0
Peptide(-Arg)	0
Peptide(-Leu)	0
Peptide(-Lys)	0
Peptide(-Tyr)	0
Peptidyl-aminoacyl-tRNA	0
Peptidyl-tRNA	0
Phosphomannan mannosephosphate	0
Piperazine citrate	0
Poligeenan	0
Poly(ADPribose)	0
Poly(G)	0
Poly-L-glutamate	0
Poly-beta-hydroxybutyrate	0
Poly-gamma-D-glutamate	0
Poly[(R)-3-hydroxyoctanoate]x	0
Polymyxin B sulfate	0
Polynucleotide 5'-diphosphate	0
Polyproline	0
Polysialic acid acetylated at O-7	0
Polysulfate of cellulose	0
Povidone-iodine	0
Prenyl-Cys methyl esters	0
Pteroylpoly-gamma-glutamate	0
Quinacetol sulfate	0
RNA (poly(A))	0
RNA (poly(C))	0
RNA (poly(U))	0
RNA(circular)	0
Rolitetracycline nitrate	0
Single-stranded nucleotide	0
Solutol HS 15	0
Styrene-acrylonitrile copolymer	0
Styrene-butadiene copolymer	0
Thermobiszeaxanthin	0
Thermobiszeaxanthin-13-13	0
Thermobiszeaxanthin-13-15	0
Thermobiszeaxanthin-15-15	0
Thermocryptoxanthin	0
Thermocryptoxanthin-11	0
Thermocryptoxanthin-13	0
Thermocryptoxanthin-15	0
Thermozeaxanthin	0
Thermozeaxanthin-13	0
Thermozeaxanthin-15	0
Thermozeaxanthin-17	0
Thymine dimer	0
Two thymine residues (in DNA)	0
Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl)-D-alanyl-D-alanine	0
Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl-L-alanyl)-D-alanyl-D-alanine	0
Vinyl chloride-vinyl acetate copolymer	0
Vinylidene chloride-vinyl chloride copolymer	0
Zanapezil fumarate	0
[Arabino-galacto-(1->6)]-(1->3)-beta-D-galactans	0
[Glu(-Cys)]n-Gly	0
a long-chain acid anion	0
acrylic polymer +	0
alpha-2,8-linked polymer of sialic acid	0
alpha-Semegma mycolic acid	0
atactic polymer	0
cis-Prenyl-tRNA	0
conjugated polymer	0
copolymer +	0
copovidone	0
denatured polymer	0
dendritic polymer	0
depurinated DNA	0
ditrans,polycis-heptaprenyl diphosphate	0
ditrans,polycis-hexaprenyl diphosphate	0
ditrans,polycis-nonaprenyl diphosphate	0
ditrans,polycis-octaprenyl diphosphate	0
glass +	0
glycopolymer +	0
graft polymer	0
heteropolyacid polymer +	0
homopolymer +	0
hyperbranched polymer	0
ionic polymer +	0
ionomer +	0
isotactic polymer	0
lentinan	7
lignocellulose	0
m7G(5')pppRm-RNA (mRNA containing an 2'-O-methylpurine cap)	0
maneb +	998
methylated polymer	0
metiram	24
oligoglycosylglucose	0
oligoglycosylglucosylceramide	0
oligophosphate	0
oligosaccharide containing 6-methyl-D-glucose units	0
para-Aramid fibrils	0
peptidyl-L-lysyl-peptide	0
peptidyl-allysyl-peptide	0
peptidylglycine	0
phenol formaldehyde resin	0
poly(amide) polymer +	0
poly(aryleneethynylene) polymer	0
poly(ether) polymer +	0
poly(melamine) polymer	0
poly(silane) polymer +	0
poly(sulfide) polymer	0
poly[(1''->2')-ADP-alpha-D-ribose] +	0
poly[(1''->2')-ADP-alpha-D-ribose] group	0
poly[(R)-3-hydroxybutanoate]n-x	0
poly[(R)-3-hydroxyoctanoate]n	0
polyamine polymer +	0
polyaniline polymer +	0
polyarylene polymer +	0
polycarbonate polymer +	0
polyester polymer +	0
polyimide polymer	0
polysiloxane polymer +	0
polysilsesquioxane polymer	0
protein C-terminal S-farnesyl-L-cysteine	0
protein C-terminal S-farnesyl-L-cysteine methyl ester	0
rRNA containing N(1)-methylguanine	0
rRNA containing N(6)-methyladenine	0
rubber particle	0
soluble variant-surface-glycoprotein	0
syndiotactic polymer	0
tRNA 3-(3-amino-3-carboxypropyl)-uridine	0
tRNA UPsiC	0
tRNA adenine	0
tRNA containing 2-thiouridine	0
tRNA containing 5-aminomethyl-2-thiouridine	0
tRNA containing 5-carboxymethylaminomethyl-2-thiouridine	0
tRNA containing 5-methylaminomethyl-2-thiouridylate	0
tRNA containing 5-methylcytosine	0
tRNA containing 6-isopentenyladenosine	0
tRNA containing N(1)-methyladenine	0
tRNA containing N(1)-methylguanine	0
tRNA containing N(2)-methylguanine	0
tRNA containing N(6)-methyladenine	0
tRNA containing N(7)-methylguanine	0
tRNA containing thymine	0
tRNA cytosine	0
tRNA guanine	0
tRNA precursor	0
tRNA pseudouridine	0
tRNA queuine	0
tRNA uridine	0
tRNA with a 3' CC end	0
tRNA with a 3' CCA end	0
tRNA with a 3' cytidine	0
tRNA(Asp)-queuosine	0
tRNA(Tyr) containing 2'-O-methylguanosine	0
tactic polymer	0
teichuronic acid	0
tetrahydrofolyl-poly(glutamic acid) polymer +	0
tyloxapol	18
variant-surface-glycoprotein 1,2-didecanoyl-sn-phosphatidylinositol	0
Path 2
Term	Annotations
CHEBI ontology	19811
subatomic particle	19809
composite particle	19809
hadron	19840
baryon	19809
nucleon	19809
atomic nucleus	19809
atom	19809
group	19768
polyatomic entity	19767
macromolecule	8777
polymer	1026
((R)-3-Hydroxybutanoyl)(n-2)	0
(1->3)-beta-D-Galactopyranans	0
(ribonucleotide)n+m	0
1,3-beta-D-Oligoglucan	0
1,3-beta-D-Xylan	0
1,6-alpha-D-mannosyloligosaccharide	0
10-formyltetrahydrofolyl polyglutamate polymer	0
2-Polyprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone	0
2-Polyprenyl-6-hydroxyphenol	0
2-Polyprenyl-6-methoxyphenol	0
2-polyprenylphenol +	0
3-Polyprenyl-4-hydroxy-5-methoxybenzoate	0
4,4'-Diaminostilbene dihydrochloride	0
4,4'-Stilbenedicarboxamidine dihydrochloride	0
4-poly[(1''->2')-ADP-alpha-D-ribose]-L-aspartate residue	0
5-Hydroxy-2-polyprenylphenol	0
5-Oxoprolyl-tRNA	0
5-methyltetrahydrofolyl polyglutamate polymer	0
5-oxoprolyl-peptide	0
5-poly[(1''->2')-ADP-alpha-D-ribose]-L-glutamate residue	0
5S-rRNA precursor	0
Alkylated DNA	0
Aluminoparaaminosalicylate calcium	0
Amrinone lactate	0
Calcium arsenate	2
Calcium pantothenate	0
Clocapramine dihydrochloride	0
Collagen	1
Cycloguanil pamoate	0
DNA 2,6-diamino-5-formamido-3,4-dihydro-4-oxopyrimidine	0
DNA 4,6-diamino-5-formamidopyrimidine	0
DNA 5-methylcytosine	0
DNA 6-methylaminopurine	0
DNA N(4)-methylcytosine	0
DNA adenine	0
DNA containing 6-O-methylguanine	0
DNA containing guanine	0
DNA cytosine	0
Dimethylaminoethyl reserpilinate dihydrochloride	0
Ferric gluconate	0
Glucosylated DNA	0
HR1917	0
Hexadimethrine bromide	8
Iminoctadine acetate	0
Isomaltosaccharide	0
Kad 1229	0
L-Lysyl-tRNA(Pyl)	0
L-Pyrrolysyl-tRNA(Pyl)	0
L-arginyl-protein	0
L-glutaminyl-peptide	0
L-leucyl-protein	0
L-methionylaminoacyl-tRNA	0
Lactitol dihydrate	0
Laureth 4	0
Linear DNA duplexes	0
Mebhydrolin napadisilate	1
Meglumine sodium amidotrizoate	1
N-Substituted aminoacyl-tRNA	0
N-formyl-L-methionylaminoacyl-tRNA	0
Nonoxynol-9 iodine	0
Nylon 6	0
O-Methylated RNA	0
O-Phosphoseryl-tRNA(Cys)	0
O-Phosphoseryl-tRNA(Sec)	0
Oligoribonucleotide	0
Oligosaccharides with 4-deoxy-alpha-D-gluc-4-enuronosyl group	0
Oligosaccharides with terminal 4-deoxy-6-methyl-alpha-D-galact-4-enuronosyl groups	0
Oligouronides	0
Oxyquinoline sulfate	0
Peptide(-Arg)	0
Peptide(-Leu)	0
Peptide(-Lys)	0
Peptide(-Tyr)	0
Peptidyl-aminoacyl-tRNA	0
Peptidyl-tRNA	0
Phosphomannan mannosephosphate	0
Piperazine citrate	0
Poligeenan	0
Poly(ADPribose)	0
Poly(G)	0
Poly-L-glutamate	0
Poly-beta-hydroxybutyrate	0
Poly-gamma-D-glutamate	0
Poly[(R)-3-hydroxyoctanoate]x	0
Polymyxin B sulfate	0
Polynucleotide 5'-diphosphate	0
Polyproline	0
Polysialic acid acetylated at O-7	0
Polysulfate of cellulose	0
Povidone-iodine	0
Prenyl-Cys methyl esters	0
Pteroylpoly-gamma-glutamate	0
Quinacetol sulfate	0
RNA (poly(A))	0
RNA (poly(C))	0
RNA (poly(U))	0
RNA(circular)	0
Rolitetracycline nitrate	0
Single-stranded nucleotide	0
Solutol HS 15	0
Styrene-acrylonitrile copolymer	0
Styrene-butadiene copolymer	0
Thermobiszeaxanthin	0
Thermobiszeaxanthin-13-13	0
Thermobiszeaxanthin-13-15	0
Thermobiszeaxanthin-15-15	0
Thermocryptoxanthin	0
Thermocryptoxanthin-11	0
Thermocryptoxanthin-13	0
Thermocryptoxanthin-15	0
Thermozeaxanthin	0
Thermozeaxanthin-13	0
Thermozeaxanthin-15	0
Thermozeaxanthin-17	0
Thymine dimer	0
Two thymine residues (in DNA)	0
Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl)-D-alanyl-D-alanine	0
Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-gamma-D-glutamyl-L-lysyl-(L-alanyl-L-alanyl)-D-alanyl-D-alanine	0
Vinyl chloride-vinyl acetate copolymer	0
Vinylidene chloride-vinyl chloride copolymer	0
Zanapezil fumarate	0
[Arabino-galacto-(1->6)]-(1->3)-beta-D-galactans	0
[Glu(-Cys)]n-Gly	0
a long-chain acid anion	0
acrylic polymer +	0
alpha-2,8-linked polymer of sialic acid	0
alpha-Semegma mycolic acid	0
atactic polymer	0
cis-Prenyl-tRNA	0
conjugated polymer	0
copolymer +	0
copovidone	0
denatured polymer	0
dendritic polymer	0
depurinated DNA	0
ditrans,polycis-heptaprenyl diphosphate	0
ditrans,polycis-hexaprenyl diphosphate	0
ditrans,polycis-nonaprenyl diphosphate	0
ditrans,polycis-octaprenyl diphosphate	0
glass +	0
glycopolymer +	0
graft polymer	0
heteropolyacid polymer +	0
homopolymer +	0
hyperbranched polymer	0
ionic polymer +	0
ionomer +	0
isotactic polymer	0
lentinan	7
lignocellulose	0
m7G(5')pppRm-RNA (mRNA containing an 2'-O-methylpurine cap)	0
maneb +	998
methylated polymer	0
metiram	24
oligoglycosylglucose	0
oligoglycosylglucosylceramide	0
oligophosphate	0
oligosaccharide containing 6-methyl-D-glucose units	0
para-Aramid fibrils	0
peptidyl-L-lysyl-peptide	0
peptidyl-allysyl-peptide	0
peptidylglycine	0
phenol formaldehyde resin	0
poly(amide) polymer +	0
poly(aryleneethynylene) polymer	0
poly(ether) polymer +	0
poly(melamine) polymer	0
poly(silane) polymer +	0
poly(sulfide) polymer	0
poly[(1''->2')-ADP-alpha-D-ribose] +	0
poly[(1''->2')-ADP-alpha-D-ribose] group	0
poly[(R)-3-hydroxybutanoate]n-x	0
poly[(R)-3-hydroxyoctanoate]n	0
polyamine polymer +	0
polyaniline polymer +	0
polyarylene polymer +	0
polycarbonate polymer +	0
polyester polymer +	0
polyimide polymer	0
polysiloxane polymer +	0
polysilsesquioxane polymer	0
protein C-terminal S-farnesyl-L-cysteine	0
protein C-terminal S-farnesyl-L-cysteine methyl ester	0
rRNA containing N(1)-methylguanine	0
rRNA containing N(6)-methyladenine	0
rubber particle	0
soluble variant-surface-glycoprotein	0
syndiotactic polymer	0
tRNA 3-(3-amino-3-carboxypropyl)-uridine	0
tRNA UPsiC	0
tRNA adenine	0
tRNA containing 2-thiouridine	0
tRNA containing 5-aminomethyl-2-thiouridine	0
tRNA containing 5-carboxymethylaminomethyl-2-thiouridine	0
tRNA containing 5-methylaminomethyl-2-thiouridylate	0
tRNA containing 5-methylcytosine	0
tRNA containing 6-isopentenyladenosine	0
tRNA containing N(1)-methyladenine	0
tRNA containing N(1)-methylguanine	0
tRNA containing N(2)-methylguanine	0
tRNA containing N(6)-methyladenine	0
tRNA containing N(7)-methylguanine	0
tRNA containing thymine	0
tRNA cytosine	0
tRNA guanine	0
tRNA precursor	0
tRNA pseudouridine	0
tRNA queuine	0
tRNA uridine	0
tRNA with a 3' CC end	0
tRNA with a 3' CCA end	0
tRNA with a 3' cytidine	0
tRNA(Asp)-queuosine	0
tRNA(Tyr) containing 2'-O-methylguanosine	0
tactic polymer	0
teichuronic acid	0
tetrahydrofolyl-poly(glutamic acid) polymer +	0
tyloxapol	18
variant-surface-glycoprotein 1,2-didecanoyl-sn-phosphatidylinositol	0

paths to the root